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1. Introduction 
Globally, hepatocellular carcinoma (HCC) is the fifth most common cancer and the third 
highest cause of cancer-associated deaths. Although the development of HCC has been linked 
to exposure to various toxins or infectious agents, the majority of HCC cases are associated 
with chronic hepatitis B virus (HBV) infections [reviewed in (Block et al, 2003; Seeger et al, 
2007)]. Worldwide, there are an estimated 350 million cases of chronic HBV infections, and 
approximately 25% of chronically HBV-infected individuals will eventually develop HCC 
[(Beasley et al, 1981); reviewed in (Seeger et al, 2007)]. The high global incidence of chronic 
HBV infections, high mortality rate of individuals with HCC, increased prevalence of HCC, 
and the close association between chronic HBV infections and HCC development have 
generated intense interest in understanding the molecular mechanisms that underlie the 
development of HBV-induced HCC. In this chapter, we provide a review of HBV biology and 
potential mechanisms that link a chronic HBV infection to the development of HCC. We 
specifically focus on activities of the HBV X protein (HBx), a multifunctional HBV protein that 
can alter hepatocyte physiology and stimulate HBV replication. While a brief survey of HBx 
activities that could influence HCC development is provided, we emphasize HBx regulation of 
intracellular calcium signaling and cell proliferation pathways as HBx activities that could 
potentially influence hepatocyte transformation. 
2. Hepatitis B virus 
HBV is a member of the Hepadnaviridae, a family of hepatotropic viruses that predominately 
infect hepatocytes in their respective hosts; similar viruses have been isolated from apes, 
woodchucks, squirrels, ducks, geese, and cranes [reviewed in (Seeger et al, 2007)]. HBV has 
a highly compact DNA genome of about 3200 nucleotides in length that contains four 
overlapping open reading frames (ORFs); every nucleotide of the genome is in at least one 
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open reading frame (Figure 1). The four overlapping ORFs of the HBV genome encode 
seven proteins: the reverse transcriptase/polymerase, the pre-core (E antigen) and core 
(capsid) proteins, three envelope (large, middle, and small hepatitis B surface antigens) 
proteins, and the nonstructural X protein (HBx) [reviewed in (Seeger et al, 2007)]. The cell-
surface receptor of HBV that facilitates HBV infection of hepatocytes has not been 
conclusively identified, and the mechanism by which HBV enters hepatocytes is not clear. 
Upon infection of hepatocytes, the encapsidated, partially double-stranded DNA genome is 
transported to the nucleus, where it is converted into a covalently closed, double-stranded, 
circular DNA (cccDNA). cccDNA is the template for all HBV RNA transcripts; the 
transcripts are exported out of the nucleus into the cytoplasm and are translated to form the 
HBV pre-core, core, envelope, reverse transcriptase/polymerase, and HBx proteins. The 
largest HBV RNA transcript, the pregenomic RNA (pgRNA), is packaged with the reverse 
transcriptase into viral capsids in the cytosol and is reverse transcribed to generate the 
partially double-stranded HBV DNA genome [reviewed in (Seeger et al, 2007)]. HBV viral 
capsids containing the replicating genome bud into the endoplasmic reticulum by 
envelopment within the HBV envelope proteins and are secreted from the infected 
hepatocyte [reviewed in (Nguyen et al, 2008; Seeger et al, 2007)]. 
2.1 Model systems for studying HBV infections 
Each member of the hepadnavirus family has a narrow host range that is thought to be 
defined primarily by the interaction between the virus and a specific receptor that is present 
on the surface of host hepatocytes [reviewed in (Seeger et al, 2007)]. Available cell culture 
systems for studying the life cycle of the Hepadnaviridae are limited. Typically, members of 
the hepadnavirus family can only directly infect hepatocytes within the liver of their 
respective avian or mammalian hosts or cultured, well-differentiated primary hepatocytes 
that are derived from these hosts; this has hampered the capabilities of researchers to study 
a natural HBV infection [reviewed in (Koike, 2009; Seeger et al, 2007)]. Chimpanzees are the 
most relevant animal model for studying the consequences of an HBV infection; however, 
due to cost and ethical reasons, studies in chimpanzees are limited (Prince & Brotman, 2001). 
HBV infections in chimpanzees also do not completely mimic all aspects of an HBV infection 
in humans; chimpanzees chronically infected with HBV usually do not develop liver 
cirrhosis or HCC (Prince & Brotman, 2001). HBV-transgenic mice have served as an 
important small animal model for studying in vivo HBV replication and immune-mediated 
HBV clearance from hepatocytes [(Guidotti et al, 1995); reviewed in (Guidotti & Chisari, 
2006)]. However, because HBV-transgenic mice contain a copy of the HBV genome that is 
integrated into the genome of all hepatocytes in these mice, the consequences of chronic 
inflammation for the development of HBV-associated HCC cannot be studied in this model 
[reviewed in (Bouchard & Navas-Martin, 2011)]. More recently, human hepatocyte chimeric 
mice, which were generated by the replacement of the majority of the mouse hepatocytes 
with implanted human hepatocytes, have been used to study HBV infections in what may 
become a more experimentally tractable and relevant model than other currently available 
small animal model systems (Tsuge et al, 2005). Mice with humanized-livers that were 
inoculated with HBV had high levels of HBV viremia that lasted for up to 22 weeks 
(Tsuge et al, 2005). Hydrodynamic transfection of the HBV genome into mouse livers has 
also been used as a method for studying HBV replication in hepatocytes; however, due to 
rapid clearance of the virus, persistent HBV infection cannot be studied in this system 
(Keasler et al, 2007). The paucity of in vivo models for studying direct HBV infections, and 
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the limited availability of cultured primary human hepatocytes, has lead many 
researchers to study HBV replication and the activities of HBV-encoded proteins in 
immortalized or transformed liver cell lines and in cultured primary hepatocytes derived 
from small animal models such as rats or mice [reviewed in (Bouchard & Navas-Martin, 
2011; Seeger et al, 2007)]. Use of these systems necessitates the bypass of the initial 
receptor-mediated infection of the cell by direct transfection of the HBV DNA genome. 
Although studies in immortalized or transformed cells have served as powerful models 
for studying various aspects of HBV replication and the functions of HBV-encoded 
proteins, these studies have also demonstrated that the activities of HBV proteins may 
vary in different cellular contexts [reviewed in (Bouchard & Navas-Martin, 2011; Neuveut 
et al, 2010)]. Studies in cultured primary hepatocytes have begun to clarify HBV 
replication strategies and the function of HBV proteins in a more relevant context 
[reviewed in (Bouchard & Navas-Martin, 2011)]. Recently, cultured primary rat 
hepatocytes have been used to study HBV replication and functions of the HBx protein 
(Clippinger & Bouchard, 2008; Clippinger et al, 2009; Gearhart & Bouchard, 2010a; 
Gearhart & Bouchard, 2010b); HBx activities in cultured primary rat hepatocytes were 
similar to HBx activities in cultured primary human hepatocytes, supporting the use of 
cultured primary rat hepatocytes as a good model system for studying the impact of HBV 
on hepatocyte physiology (Gearhart & Bouchard, 2011). 
 
Fig. 1. Schematic depiction of the HBV genome. HBV DNA is denoted by bold lines with 
black arrows, HBV open reading frames (ORFs) are represented by inner arrows shown in 
gray, and HBV mRNAs are represented by outer arrows shown in white. See text for 
detailed description. 
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2.2 HBV and hepatocellular carcinoma 
Common modes of HBV transmission include exposure to HBV-contaminated blood, unsafe 
injection practices, sexual contact with an HBV-infected individual, and perinatal 
transmission from an HBV-infected mother to her child (WHO, 2008). HBV infections are 
classified as acute, chronic, or occult. In most people with acute or short-term HBV 
infections, the infection is resolved by immune-mediated viral clearance. The inflammatory 
response to the HBV infection causes many of the symptoms that have been associated with 
hepatitis; these symptoms include jaundice, fatigue, nausea, vomiting, and abdominal pain 
[(WHO, 2008); reviewed in (Seeger et al, 2007)]. Chronic HBV infections are characterized by 
the continued presence of detectable levels of the HBV small envelope protein in the blood 
of an HBV-infected individual for more than six months [reviewed in (Lok & McMahon, 
2001)]. Chronic infections with either HBV or the hepatitis C virus (HCV) are estimated to 
account for more than 80% of primary liver cancers; approximately 60% of these liver 
cancers are attributed to chronic HBV infections and 40% to chronic HCV infections 
[reviewed in (El-Serag & Rudolph, 2007; Koike, 2009)]. Currently, the geographic locations 
with the highest incidence of HCC are areas where HBV infection is highly endemic 
[reviewed in (Pang et al, 2006)]. There are eight known genotypes of HBV, and mounting 
evidence suggests that increased persistence of an HBV infection and a greater risk for HCC 
development may be influenced by the HBV genotype in the infected individual [reviewed 
in (Chemin & Zoulim, 2009)]. Environmental factors such as alcohol consumption, aflatoxin 
exposure, and tobacco use increase the risk for developing HCC in HBV-infected 
individuals [reviewed in (Chemin & Zoulim, 2009)].  
Although the association between chronic HBV infections and HCC development is clear, 
the mechanisms that link a chronic HBV infection to HCC development are incompletely 
understood. Three potential mechanisms have been commonly invoked as consequences of 
an HBV infection that could contribute to HCC development. The first mechanism that may 
contribute to the development of HBV-associated HCC is persistent liver inflammation and 
hepatocyte proliferation that is caused by recurrent immune-mediated destruction of HBV-
infected hepatocytes and concomitant liver regeneration in chronically HBV-infected 
individuals [reviewed in (Bouchard & Navas-Martin, 2011; Guidotti & Chisari, 2006)]. 
Persistent liver inflammation can cause fibrosis and cirrhosis and may eventually select for 
hepatocytes that have accumulated tumorigenic properties [reviewed in (Bouchard & 
Navas-Martin, 2011; Chemin & Zoulim, 2009)]. Chronic liver inflammation, the associated 
elevation of reactive oxygen species (ROS), and the potential for ROS to cause DNA damage 
may also produce a more cancer-prone environment [reviewed in (Chemin & Zoulim, 
2009)]. The second mechanism that has been proposed to contribute to the development of 
HBV-associated HCC is the possible consequence of HBV genome integration into the host 
genome, which could cause genetic or epigenetic changes and genomic instability [reviewed 
in (Chemin & Zoulim, 2009; Neuveut et al, 2010)]. Integration of the HBV genome into the 
host genome could potentially result in the loss of tumor suppressive functions and/or the 
gain of tumor-promoting activities [reviewed in (Chemin & Zoulim, 2009)]. The third 
mechanism that has been proposed to be involved in the development of HBV-associated 
HCC, and the primary focus of this chapter, is the alteration of hepatocyte physiology and 
stimulation of HBV replication that is linked to expression of the HBV HBx protein 
[reviewed in (Bouchard & Navas-Martin, 2011; Koike, 2009; Neuveut et al, 2010)]. The 
multifunctional HBx protein has been shown to affect numerous cellular signaling pathways 
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that could influence HBV replication, hepatocyte transformation, and HCC development 
[reviewed in (Benhenda et al, 2009; Koike, 2009; Neuveut et al, 2010)]. Although this chapter 
focuses on HBx activities, it is important to note that in the context of an HBV infection, 
multiple mechanisms are likely to influence HCC development. 
3. HBx 
HBx is a 154 amino acid, 17 kDa, multifunctional protein that is encoded by the smallest 
open reading frame of the HBV genome. HBx can stimulate HBV replication and modulate 
intracellular calcium signaling, cell proliferation and apoptotic pathways, signal 
transduction pathways, and the activity of various transcription factors and the proteasome 
(Figure 2) [reviewed in (Benhenda et al, 2009; Bouchard & Schneider, 2004; Koike, 2009)]. 
Because HBx activities appear to be influenced by the cell type and the method of HBx 
expression used in a study, not all HBx functions in normal hepatocytes and in the context 
of HBV replication are completely understood. Most studies that have assessed the effects of 
HBx have been performed in immortalized or transformed cells, when HBx was expressed 
at higher levels than observed during HBV replication, and when HBx was expressed 
outside of the context of HBV replication. Because HBx is expressed at low levels during 
HBV replication, it has been difficult to establish systems in which HBx interacting partners 
or HBx activities can be easily studied in the context of HBV replication. Consequently, the 
use of various cellular model systems to study HBx has sometimes identified seemingly 
discrepant HBx activities. It is important to note however, that many studies that have 
analyzed HBx activities in systems where HBx is expressed in the context of HBV replication 
and in normal hepatocytes have confirmed HBx activities that were identified when HBx  
 
Fig. 2. Schematic representation of HBx activities. HBx is a multifunctional protein known to 
regulate HBV replication, numerous signal transduction pathways, the cell cycle, apoptosis, 
and transcription. HBx can also bind multiple cellular proteins. One or more of these HBx 
activities could contribute to the development of HBV-associated HCC. See text for 
references and details. 
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was overexpressed out of the context of HBV replication, suggesting that studies in various 
cellular systems can provide valuable insights into HBx activities [reviewed in (Benhenda et 
al, 2009; Bouchard & Schneider, 2004; Koike, 2009)]. Moreover, because HBx is often 
expressed in HBV-associated liver tumor cells even when expression of other HBV proteins 
is not detectable (Wang et al, 2004b; Wollersheim et al, 1988), studies in immortalized or 
transformed cells may help identify HBx activities that could be present in transformed cells 
but absent in normal hepatocytes. Overall, it is likely that studies in immortalized or 
transformed cells, in cultured primary hepatocytes, in the livers of available animal models, 
and when HBx is expressed in the absence of other HBV proteins and in the context of HBV 
replication each contribute important information regarding the various activities of this 
protein. Considering the compact nature of the HBV genome, the limited number of 
proteins encoded by the HBV genome, and the necessity for these proteins to perform their 
functions in an environment that may not favor viral replication, it is not surprising that 
HBV proteins such as HBx, which is the only regulatory protein encoded by the HBV 
genome, have multiple functions that impact HBV replication and cellular physiology. 
3.1 HBx and HBV replication 
Many studies have indicated that replication of mammalian hepadnaviruses is stimulated 
by their respective X proteins. Two different studies performed in woodchucks showed that 
the woodchuck hepatitis virus (WHV) X protein (WHx) is absolutely required for WHV 
replication in the livers of woodchucks (Chen et al, 1993; Zoulim et al, 1994); however, in 
one dissenting study, another group detected a very low level of WHV replication in 
woodchucks infected with an WHx-deficient WHV mutant (Zhang et al, 2001). Evidence 
that HBx stimulates HBV replication has been generated from studies in various mouse 
models and cell culture systems. Transgenic mice were generated with either a wild-type 
HBV genome or a mutant form of the HBV genome that did not express HBx; HBV 
replication was detected in both the wildtype HBV and mutant HBV-transgenic mice (Xu et 
al, 2002). However, when the HBx-deficient HBV-transgenic mice were bred with HBx-
transgenic mice, higher levels of circulating HBV viremia and higher levels of HBV core and 
envelope proteins were detected in the double transgenic mice than in their HBx-deficient, 
HBV-transgenic counterparts (Xu et al, 2002). These studies suggest that although HBx may 
not be absolutely required for HBV replication in this model system, HBx does enhance 
HBV replication in the livers of these mice. An important caveat to the studies in HBV-
transgenic mice is that these mice do not produce nuclear HBV cccDNA and may not 
recapitulate all aspects of authentic HBV replication (Guidotti et al, 1995). Additional 
evidence that HBx stimulates HBV replication has come from a study where mice were 
hydrodynamically injected with a plasmid encoding the wild-type HBV genome or a mutant 
HBx-deficient HBV genome (Keasler et al, 2007). The results of these studies demonstrated 
that although HBx was not absolutely required for HBV replication, there was a very 
significant decrease in HBV replication in mice injected with the HBx-deficient HBV as 
compared to mice injected with the wildtype HBV genome (Keasler et al, 2007). 
Interestingly, when a plasmid encoding HBx was co-injected with a plasmid encoding the 
mutant HBx-deficient HBV genome, HBV replication levels were restored to those seen in 
mice injected with the plasmid encoding wild-type HBV (Keasler et al, 2007). Finally, studies 
in mice with humanized livers showed that after direct infection with wild-type HBV or an 
HBx-deficient HBV, HBV replication was only seen in the livers of mice that were infected 
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with wild-type HBV (Tsuge et al, 2010; Tsuge et al, 2005). HBx expression also stimulates 
HBV replication in HepG2 cells, a human hepatoblastoma cell line, and in cultured primary 
rat hepatocytes [reviewed in (Bouchard & Schneider, 2004)]. Although most studies indicate 
that HBV replication in Huh7 cells, a human hepatoma cell line, is not regulated by HBx 
expression, a recent study demonstrated that HBx can also stimulate HBV replication in 
Huh7 cells (Lim et al, 2010). Many of the signaling pathways that are modulated by HBx, 
and will be discussed in the following sections of this chapter, have also been shown to 
influence HBV replication. HBx modulation of intracellular calcium signaling, activation of 
the Proline-rich tyrosine kinase 2 (Pyk2)/Focal adhesion kinase (FAK)-Src-Ras-Raf-MAPK 
signaling pathway, regulation of transcription pathways, interaction with ultraviolet DNA 
damage binding protein 1 (UVDDB1), and association with proteasome factors affect HBx 
regulation of HBV replication (Bouchard et al, 2001b; Gearhart & Bouchard, 2010b; Klein et 
al, 1999; Leupin et al, 2005; Tan et al, 2009; Tang et al, 2005; Zhang et al, 2004). Overall, 
studies in various model systems suggest that the X proteins of mammalian hepadnaviruses 
have an important stimulatory role during replication of mammalian hepadnaviruses. 
3.2 HBx and hepatocellular carcinoma 
HBx expression and activities are thought to be major contributing factors in the 
development of HBV-associated HCC; however, the exact contribution of HBx to HCC 
development is unknown. One important clue that implicates HBx in the development of 
HBV-associated HCC is that chronic infections of birds with avian hepadnaviruses are not 
associated with the development of HCC [reviewed in (Seeger et al, 2007)]. The avian 
hepadnaviruses either do not encode an X protein or encode an X protein that is highly 
divergent from the X proteins of mammalian hepadnaviruses (Mandart et al, 1984; Sprengel 
et al, 1988). The mammalian hepadnaviruses all encode an X protein, and only infections 
with mammalian hepadnaviruses are associated with the development of HCC in their 
respective hosts [reviewed in (Seeger et al, 2007)]. Additional evidence for the involvement 
of HBx in HCC development has come from studies in HBx-transgenic mice. Some studies 
have shown that HBx expression can directly cause HCC in HBx-transgenic mice (Kim et al, 
1991; Yu et al, 1999). In contrast, other researchers have found that HBx expression alone is 
not sufficient for the development of liver tumors in HBx-transgenic mice but can sensitize 
these mice to chemical- or oncogene-induced HCC (Madden et al, 2001; Slagle et al, 1996; 
Terradillos et al, 1997; Zhu et al, 2004). While the reason for the observed differences in 
tumor development in the various HBx-transgenic mice has not been completely explored 
and may be related to the genetic background of the mice and/or the level of HBx 
expression, studies in these HBx-transgenic mice strongly support the notion that HBx can 
have at least a co-factor role in the development of HCC. Importantly, a co-factor role for 
HBx in the development of HBV-associated HCC is more consistent with the biology of 
HCC development in chronically HBV-infected individuals; development of HCC in 
chronically HBV-infected individuals can take decades to arise [reviewed in (Seeger et al, 
2007)]. The observation that HBV-associated HCC requires decades to arise suggests that 
HBV does not encode a strongly oncogenic protein but instead encodes proteins that can 
cause subtle changes to hepatocyte physiology that could sensitize hepatocytes to other 
oncogenic signals [reviewed in (Bouchard & Navas-Martin, 2011; Neuveut et al, 2010)]. The 
activities of HBx that could influence HCC development are discussed below. 
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3.3 Intracellular localization of HBx 
The primary intracellular location of HBx is the cytoplasm, although a small fraction of HBx 
can be found in the nucleus of cells (Doria et al, 1995; Haviv et al, 1998b; Henkler et al, 2001; 
Siddiqui et al, 1987; Urban et al, 1997; Vitvitski-Trepo et al, 1990). The localization of HBx is 
dependent on its level of expression. When HBx is expressed at very low levels, it is mainly 
localized to the nucleus, and when HBx is expressed at high levels, its localization is mainly 
cytoplasmic (Henkler et al, 2001). Many studies have also shown that a fraction of cytosolic 
HBx localizes to the mitochondria and can interact with the voltage-dependent anion 
channel (VDAC) 3, a component of the mitochondrial permeability transition pore (MPTP) 
(Clippinger & Bouchard, 2008; Henkler et al, 2001; Huh & Siddiqui, 2002; Kim et al, 2007; 
Rahmani et al, 2000; Shirakata & Koike, 2003; Takada et al, 1999). Cytoplasmic, nuclear, and 
mitochondrial HBx localization have been directly linked to HBx activities that regulate 
specific cellular signal transduction or transcription pathways [reviewed in (Ma et al, 2011)]. 
3.4 HBx interacts with multiple cellular proteins 
HBx has been reported to interact with various cellular proteins, such as components of the 
proteasome complex (Fischer et al, 1995; Huang et al, 1996), UVDDB1 and 2 (Becker et al, 
1998; Lee et al, 1995; Sitterlin et al, 2000)), the cell cycle regulatory protein p53 (Elmore et al, 
1997; Feitelson et al, 1993; Wang et al, 1994), the NF-B inhibitory protein IB- (Weil et al, 
1999), and VDAC3 (Rahmani et al, 2000; Rahmani et al, 1998), to name a few. HBx can also 
interact with components of the general transcription machinery such as the TATA-binding 
protein (TBP), the RBP5 subunit of RNA polymerase, and the general transcription factors 
TFIIB and TFIIH [(Aufiero & Schneider, 1990; Barnabas et al, 1997; Cheong et al, 1995; Haviv 
et al, 1998a; Haviv et al, 1998b; Maguire et al, 1991; Williams & Andrisani, 1995; Yang et al, 
1999); reviewed in (Bouchard & Schneider, 2004)]. While the potential association of HBx 
with many cellular proteins could explain the multifunctional nature of HBx, because many 
studies that have analyzed HBx-interacting proteins were conducted in systems in which 
both HBx and these proteins were overexpressed, whether all of these interactions exist in 
normal hepatocytes when HBx is expressed during HBV replication remains to be 
determined. Due to space limitations, the following sections will focus on the interaction of 
HBx with UVDDB1 and 2 and p53; these interactions have been studied by various groups 
and may play an important role in HBV-induced HCC (Feitelson et al, 1993; Lee et al, 1995; 
Sitterlin et al, 2000; Wang et al, 1994). A more extensive discussion of proteins that may 
interact with HBx can be found in recently published reviews of this topic (Arbuthnot et al, 
2000; Benhenda et al, 2009; Wei et al, 2010; Zhang et al, 2006). 
3.4.1 HBx and UVDDB1 and 2 
UVDDB1 associates with UVDDB2 to form the UV-DDB complex, which functions in 
nucleotide excision repair. The UVDDB complex also interacts with the transcription factor 
E2F1, indicating a role for the UVDDB complex in both DNA repair and cell cycle control 
[(Datta et al, 2001; Hayes et al, 1998); reviewed in (Butel et al, 1996)]. Results from yeast-2-
hybrid screens indicated that HBx can directly interact with UVDDB1 (Lee et al, 1995; Lin-
Marq et al, 2001; Sitterlin et al, 2000). Further evidence for an interaction between 
hepadnavirus X proteins and the UVDDB complex was provided from studies performed 
with WHV; these studies confirmed an interaction between WHx and UVDDB1 (Bergametti 
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et al, 2002). Disruption of the WHx-UVDDB1 interaction inhibited WHV replication in 
woodchucks, indicating that WHx and UVDDB1 must associate in order for WHV 
replication to occur in vivo (Sitterlin et al, 2000). WHx was also shown to interact with 
UVDDB2. The interaction between WHx and UVDDB1 stabilized WHx by protecting it from 
proteasomal degradation, but the interaction between UVDDB1 and UVDDB2 and between 
HBx and UVDDB2 counteracted this protection (Bergametti et al, 2002). In one study, HBx 
altered UVDDB1 activity, resulting in decreased cell viability (Lin-Marq et al, 2001). Similar 
to the required interaction of WHx and UVDDB1 for WHV replication, HBx association with 
UVDDB1 was also shown to be required for HBV replication (Sitterlin et al, 2000). HBx 
expression diminished the innate ability of cells to repair DNA damage, and the results of a 
study in HepG2 cells suggested that the binding of HBx to UVDDB1 inhibits normal 
UVDDB1 functions and can result in chromosome segregation defects (Becker et al, 1998; 
Martin-Lluesma et al, 2008). Results from studies in HBx-transgenic mice, however, 
indicated that the expression of HBx did not significantly increase the accumulation of 
spontaneous mutations, implying that although the interaction between HBx and UVDDB1 
may inhibit the ability of cells to repair DNA damage, this interaction is not directly 
mutagenic (Madden et al, 2000). Interestingly, it has been suggested that the interaction 
between HBx and UVDDB1 may be involved in the HBx-related cell cycle arrest at the G1/S 
phase border [reviewed in (Bouchard & Schneider, 2004)]. Overall, a decreased ability to 
repair DNA damage caused by the interaction of HBx with the UVDDB complex, combined 
with modulation of cell proliferation pathways, could be important factors in the 
development of HBV-associated HCC. 
3.4.2 HBx and p53 
The results of various studies suggest that HBx may interact with the tumor suppressor p53 
both in vivo and in vitro. HBx that was tagged with glutathione S-transferase (GST-HBx) was 
shown to interact with in vitro translated p53; a reciprocal interaction between GST-p53 and 
in vitro translated HBx was also observed (Wang et al, 1994). p53 and HBx produced by in 
vitro translation and subsequently co-immunoprecipitated with either anti-HBx or anti-p53 
antibodies also confirmed an interaction between p53 and HBx (Feitelson et al, 1993). 
Several reports indicate that HBx can alter the sequence-specific DNA binding and 
transcriptional regulatory capacity of p53 as well as p53 stimulation of apoptotic pathways 
(Elmore et al, 1997; Lee & Rho, 2000; Wang et al, 1994; Wang et al, 1995). The results of one 
study suggested that HBx can interact with the carboxy-terminal domain of p53 and that 
this interaction leads to inhibition of p53-induced apoptosis in normal primary human 
fibroblasts (Wang et al, 1995). Results of another study suggested that p53 can be 
sequestered in the cytoplasm by HBx, thus leading to the inhibition of p53-mediated 
apoptosis (Elmore et al, 1997). Interestingly, there are varying results regarding the role of 
p53 in the regulation of apoptosis by HBx; both p53-dependent (Wang et al, 2008) and p53-
independent regulation of apoptosis by HBx have been observed (Shintani et al, 1999; 
Terradillos et al, 1998). Studies have also interrogated the influence of p53 on HBx 
regulation of the cyclin-dependent kinase inhibitor, p21; HBx increased the level of p21 in 
NIH3T3 cells in the presence of p53 but did not increase the level of p21 when p53 was 
knocked down (Ahn et al, 2002). However, in a different study, HBx increased p21 levels in 
Hep3B cells, a p53 mutant HCC cell line (Park et al, 2000). Since activities of HBx that were 
linked to p53-dependent pathways were also observed in the absence of p53, the functional 
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importance of the putative interaction between p53 and HBx has been questioned 
(Groisman et al, 1999; Terradillos et al, 1998). In one study, an in vivo interaction between 
HBx and p53 was observed in liver tissues of HBV-infected patients with HCC; however, 
contradictory results were obtained in a different study where p53 was found to be present 
only in the nucleus and HBx predominantly in the cytoplasm of liver tissues of HBV-
infected patients (Feitelson et al, 1993; Su et al, 2000). The effect of HBx on the activities of 
p53 could directly influence the development of HBV-associated HCC; deregulation of p53 
activities, such as its ability to regulate the cell cycle and apoptotic pathways, could favor 
processes that cause hepatocyte transformation. Overall, studies that have addressed a 
potential interaction between HBx and p53 suggest that this may occur in a cell-specific 
context; additional studies are required to examine whether HBx and p53 interact in the 
context of HBV replication in normal hepatocytes.  
3.5 HBx activates transcription 
Although HBx does not bind directly to DNA, it can function as a modest transcriptional 
activator [reviewed in (Benhenda et al, 2009; Bouchard & Schneider, 2004; Koike, 2009)]. 
HBx can activate multiple viral and cellular transcription promoters and enhancers 
[reviewed in (Benhenda et al, 2009; Murakami, 2001; Yen, 1996)]. HBx can activate 
promoters that contain DNA binding sites for transcription factors such as nuclear factor-
kappa-B (NF-B), activating protein-1 (AP-1), nuclear factor of activated T cells (NFAT), 
cAMP response element-binding transcription factor (CREB)/activating transcription factor 
(ATF)-2, CCAAT/enhancer binding protein (C/EBP), and stimulating protein 1 (Sp1), to 
name a few (Carretero et al, 2002; Chirillo et al, 1996; Cougot et al, 2007; Doria et al, 1995; 
Lara-Pezzi et al, 1999; Lee et al, 1998; Lucito & Schneider, 1992; Maguire et al, 1991; Mahe et 
al, 1991; Natoli et al, 1994a; Purcell et al, 2001; Spandau & C., 1988; Su & Schneider, 1996; 
Waris et al, 2001; Williams & Andrisani, 1995). HBx can activate transcription factors 
directly, through interactions with specific transcription regulatory proteins, or indirectly, 
by activation of cytosolic signal transduction pathways [(reviewed in (Bouchard & 
Schneider, 2004)]. HBx can directly interact with components of the basal transcription 
machinery, such as TBP, RBP5, TFIIB, and TFIIH; in addition, it also interacts with CREB 
and c-AMP dependent transcription factor (ATF)-3, a member of the basic leucine zipper (b-
Zip) family of transcription factors (Aufiero & Schneider, 1990; Barnabas et al, 1997; Cheong 
et al, 1995; Cougot et al, 2007; Haviv et al, 1998a; Haviv et al, 1998b; Lin et al, 1997; Maguire 
et al, 1991; Williams & Andrisani, 1995; Yang et al, 1999). Interestingly, some studies suggest 
that HBx can activate its own promoter through an X responsive element (XRE) and can also 
activate HBV enhancers (Doria et al, 1995; Faktor & Shaul, 1990; Spandau & C., 1988). 
Whether the transcriptional activation functions of HBx in normal hepatocytes and in the 
context of HBV replication completely overlap with activities identified in established cell 
lines awaits a comprehensive analysis of HBx activities during a natural HBV infection. 
3.6 HBx activates multiple signal transduction pathways 
HBx can regulate numerous signal transduction pathways, including the Ras-Raf-Mitogen 
activated protein kinase (MAPK) pathway, the Janus-kinase signal transducer and activator 
of transcription pathway (JAK-STAT pathway), the phosphoinositide 3-kinase (PI3K) 
pathway, the stress-activated protein kinase/NH2-terminal-Jun kinase (SAPK/JNK) 
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pathway, the transforming growth factor- (TGF-) pathway, the protein kinase C (PKC) 
and the p38 mitogen-activated protein kinase (p38MAPK) pathway (Benn & Schneider, 
1994; Benn et al, 1996; Bouchard et al, 2003; Bouchard et al, 2001b; Chung et al, 2004; Cong et 
al, 1997; Cross et al, 1993; Johnson et al, 2000; Kekule et al, 1993; Klein et al, 1999; Klein & 
Schneider, 1997; Lara-Pezzi et al, 1999; Lee & Yun, 1998; Lucito & Schneider, 1992; Natoli et 
al, 1994a; Natoli et al, 1994b; Purcell et al, 2001; Tarn et al, 1999; Tarn et al, 2001; Tarn et al, 
2002; Wang et al, 1998). The results of various studies suggest that HBx regulation of 
cytosolic signal transduction pathways could play a role in activation of transcription 
factors, HBx modulation of HBV replication, and HBx modulation of apoptotic and cell 
proliferation pathways [reviewed in (Benhenda et al, 2009; Bouchard & Schneider, 2004)]. 
The various signaling pathways that are stimulated by HBx have also been linked to 
mechanisms that are associated with cell transformation. For example, the Ras-Raf-MAPK 
signaling cascade has been implicated in the regulation of cell cycle progression, cellular 
differentiation, and cellular transcription pathways [reviewed in (Boguski & McCormick, 
1993; McCubrey et al, 2007)]. HBx can activate the Ras/Raf kinase pathway in HeLa cells, a 
human cervical carcinoma cell line, and F9 cells, a mouse teratocarcinoma cell line; 
dominant negative mutants of Ras and the kinase Raf, an effector of the Ras-Raf-MAPK 
signaling cascade, blocked HBx activation of AP-1 (Natoli et al, 1994b). HBx activation of the 
Ras-Raf-MAPK signaling cascade was also observed in Chang cells, a human liver cell line, 
and directly in mouse livers (Benn & Schneider, 1994; Nijhara et al, 2001). Chang cells that 
expressed HBx had increased levels of Ras-GTP as compared to control cells, suggesting that 
HBx can increase the exchange of GDP for GTP (Benn & Schneider, 1994). Various reports 
indicate that the activation of Ras by HBx is indirect; HBx was not associated with Ras, Ras-
GAP, the GTP exchange factor sons of sevenless (Sos), or the Ras adapter proteins Grb2 or 
Shc (Benn et al, 1996; Klein & Schneider, 1997). Instead, HBx was shown to constitutively 
activate non-receptor tyrosine kinases of the Src family (Src and Fyn), which can signal to 
Ras; inhibition of Src in Chang cells blocked HBx-induced Ras signaling and activation of 
the MAPK, ERK-2 (Klein et al, 1999; Klein & Schneider, 1997). HBx activation of Src 
kinases has been linked to the HBx-induced elevation of cytosolic calcium levels and 
activation of Pyk2 and FAK (Bouchard et al, 2006; Bouchard et al, 2001b). HBx stimulation 
of Src kinases promoted cycling of growth-arrested HepG2 and Chang cells; HBx induced 
arrested cells to exit G0 but stall at the G1/S border of the cell cycle, an activity that is 
thought to be important for HBV replication (Bouchard et al, 2001a). Importantly, active 
Src kinases are required for WHV replication, and HBx activation of Pyk2 and FAK, 
which is required for HBx activation of Src kinases, is also important for HBV replication 
(Bouchard et al, 2006; Bouchard et al, 2001b; Klein et al, 1999; Klein & Schneider, 1997). 
Finally, HBx-induced activation of Src kinases has been shown to be required for the 
stimulation of p38 MAPK, STAT3, and AP-1; activation of these proteins have been linked 
to various cell transformation processes and could contribute to processes that link 
chronic HBV infections to HCC development (Klein et al, 1999; Klein & Schneider, 1997; 
Lee & Yun, 1998; Tarn et al, 2002). 
3.7 HBx regulates apoptotic pathways 
Whether HBx is anti- or pro-apoptotic has been the subject of considerable debate. HBx has 
been reported to induce apoptosis (Bergametti et al, 1999; Chami et al, 2003; Chirillo et al, 
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1997; Kim et al, 1998; Kim et al, 2008; Kim & Seong, 2003; Koike et al, 1998; Lee et al, 2004; 
Liang et al, 2007; Liu et al, 2007; Lu & Chen, 2005; Miao et al, 2006; Shintani et al, 1999; Su & 
Schneider, 1997; Su et al, 2001; Takada et al, 1999; Tanaka et al, 2004; Terradillos et al, 2002; 
Terradillos et al, 1998; Wang et al, 2004a), sensitize cells to pro-apoptotic stimuli (Lee et al, 
2004; Su & Schneider, 1997; Wang et al, 2004a), inhibit apoptosis (Clippinger et al, 2009; Diao 
et al, 2001; Elmore et al, 1997; Gottlob et al, 1998; Kang-Park et al, 2006; Lee et al, 2001; Pan et 
al, 2001; Shih et al, 2000), or have no impact on apoptosis (Klein et al, 2003; Madden et al, 
2000; Yun et al, 2002). Interestingly, the effect of HBx on apoptosis was found to differ 
depending on the differentiation status of hepatocytes; HBx sensitized dedifferentiated 
hepatocytes, but not differentiated hepatocytes, to apoptotic signals (Wang et al, 2004a). The 
differing effects of HBx expression on apoptotic pathways that have been reported are likely 
attributed to the use of numerous cell types and experimental conditions for studying HBx 
apoptotic activities, and it is now apparent that HBx activities can vary in different cellular 
environments. Few studies have analyzed the impact of HBx expression on apoptosis in the 
context of HBV replication. Recent studies in cultured primary rat hepatocytes 
demonstrated that HBx has both pro- and anti-apoptotic activities in normal hepatocytes; 
similar HBx effects were observed when HBx was expressed in the absence of other HBV 
proteins or in the context of HBV replication. The anti-apoptotic activity of HBx in cultured 
primary rat hepatocytes was linked to HBx activation of NF-B; however, when activation 
of NF-B was blocked, HBx was found to induce apoptosis through a mechanism that was 
dependent on activities of the MPTP (Clippinger et al, 2009). The exact nature of HBx 
regulation of the MPTP is currently unknown. Whether HBx regulates apoptosis to affect 
HBV replication or the spread of HBV within the infected liver is not known. It is possible 
that HBx inhibits apoptosis during early stages of an HBV infection and later induces 
apoptosis to assist in viral spread [reviewed in (Benhenda et al, 2009; Ng & Lee, 2011)]. 
Although the pro-apoptotic effects of HBx might facilitate HBV replication and spread and 
lead to evasion of host cell-mediated immunity [reviewed in (Arbuthnot et al, 2000)], a 
recent study has provided evidence that modulation of apoptosis during an HBV infection is 
unlikely to affect viral spread (Arzberger et al, 2010). It is possible that the ability of HBx to 
induce or inhibit apoptosis might change during the course of an HBV infection as the liver 
is undergoing regeneration, or when the hepatocytes undergo transformation or respond to 
cytokines such as TNF [reviewed in (Benhenda et al, 2009; Brenner, 1998; FitzGerald et al, 
1995)]; both the activation and inactivation of apoptosis by HBx could contribute to HCC 
development. Enhanced compensatory hepatocyte regeneration that is induced by an HBx 
pro-apoptotic effect could lead to selection of hepatocytes that are resistant to apoptotic 
signals, thus leading to HCC (Koike et al, 1998). Alternatively, inhibition of apoptosis by 
HBx may increase the accumulation of potentially transforming mutations, leading to the 
development of liver cancer [reviewed in (Arbuthnot et al, 2000)]. Although the precise 
mechanisms that underlie HBx regulation of apoptosis in naturally infected hepatocytes 
remain incompletely understood, HBx modulation of hepatocyte apoptotic pathways is a 
potential mechanism that could influence the development of HBV-associated HCC. 
4. HBx and the cell cycle 
4.1 Cell cycle overview 
The process of cellular replication and division is known as the cell cycle. The cell cycle is a 
highly regulated series of events and can be controlled by intracellular and extracellular 
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factors [reviewed in (Harper & Brooks, 2005)]. Differentiated cells, such as hepatocytes, are 
typically maintained in a non-dividing, resting state, known as quiescence [reviewed in 
(Taub, 2004)]. When cells are quiescent, also known as the G0 phase, they must receive a 
signal in order to exit the G0 phase and enter the cell cycle [reviewed in (Cook et al, 2000; 
Harper & Brooks, 2005; Vermeulen et al, 2003)]. If they receive this signal, they will enter 
into the first phase of the cell cycle, known as the Gap 1 (G1) phase. During G1 phase, cells 
are preparing to replicate their DNA, and as long as the first major checkpoint of the cell 
cycle, the restriction point (R) at the G1/S border, is not activated and the growth signal is 
still present, cells will proceed into the Synthesis (S) phase. During S phase, the cells 
undergo DNA replication; once cells enter into this phase, DNA replication is completed 
regardless of removal of the growth signal or the presence of DNA damage. After DNA 
replication is completed, cells enter into the Gap 2 (G2) phase where the cellular machinery 
checks for DNA damage that may have accumulated during DNA replication and prepares 
for the Mitosis (M) phase. Once the proper signals are in place for cell cycle progression, 
cells will enter into M phase, during which mitosis occurs [reviewed in (Harper & Brooks, 
2005; Vermeulen et al, 2003)]. A third checkpoint, the spindle checkpoint, exists after 
metaphase and prior to anaphase; at this checkpoint the cell employs methods to detect 
improper alignment of chromosomes on the mitotic spindle (Amon, 1999; Fang et al, 1998). 
If improper alignment is not detected, cells will continue into anaphase, at which point, the 
cells will complete the cell cycle, generating two daughter cells [reviewed in (Vermeulen et 
al, 2003)]. 
4.1.1 Positive regulators of cell cycle progression: Cyclins and cyclin-dependent 
kinases 
Transition from one phase of the cell cycle to the next is tightly regulated and progressive. 
Key regulatory proteins that control cell cycle progression are cyclins and cyclin-dependent 
kinases (CDKs). CDKs are a family of serine/threonine protein kinases that are only 
activated at certain points in the cell cycle, although their expression levels remain constant 
throughout the entire cell cycle [reviewed in (Vermeulen et al, 2003)]. Currently, there are 
five CDKs that are associated with cell cycle progression in mammalian cells: CDKs 4 and 6, 
which are active during early G1 phase, CDK2, which is active in late G1 and S phase, 
CDK1, which is active during G2 and M phase, and CDK7, which can act in combination 
with cyclin H as a CDK-activating kinase (CAK) [(Fisher & Morgan, 1994); reviewed in 
(Harper & Brooks, 2005)]. CDK activity is highly regulated and requires both the expression 
of activating proteins, cyclins, and phosphorylation of the cyclin-CDK complex [reviewed in 
(Harper & Brooks, 2005; Vermeulen et al, 2003)]. The expression of cyclins is highly 
regulated, and their levels rise and fall depending on the cell cycle phase (Evans et al, 1983; 
Pines & Hunter, 1991). There are three D type cyclins, cyclin D1, cyclin D2, and cyclin D3, 
which bind to CDK4 and CDK6, resulting in activation of these CDKs; activation of CDK4 
and CDK6 is required for entry into the cell cycle [reviewed in (Sherr, 1993; Sherr, 1994)]. 
Unlike the other cyclins, cyclin D expression is maintained as long as growth factor 
stimulation is present (Assoian & Zhu, 1997). Cyclin E binds to CDK2 and regulates cell 
cycle progression from G1 into S phase (Ohtsubo et al, 1995). Cyclin A binds to CDK2 to 
regulate S phase progression and also binds to CDK1 during late G2 and M phase to 
promote entry into M phase (Arellano & Moreno, 1997; Girard et al, 1991; King et al, 1994; 
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Walker & Maller, 1991). During mitosis, an additional cyclin, cyclin B, is expressed; cyclin B 
binds to CDK1 to regulate the remainder of mitosis (Arellano & Moreno, 1997; King et al, 
1994). In accordance with the dynamic nature of the induction of cyclin expression, cyclins are 
rapidly degraded when the cell cycle has progressed beyond the phase during which their 
expression is required. Cyclins D and E contain a PEST sequence, a segment rich in proline (P), 
glutamic acid (E), serine (S), and threonine (T) residues, and cyclins A and B contain 
destruction boxes. The PEST sequence and destruction boxes facilitate ubiquitin-mediated 
proteasomal degradation of the cyclins (Glotzer et al, 1991; Rechsteiner & Rogers, 1996). 
Full CDK activity is dependent upon proper cyclin expression and binding and 
phosphorylation of the cyclin-CDK complex. Phosphorylation of the cyclin-CDK complex 
occurs on conserved threonine and tyrosine residues and induces conformational changes, 
which can enhance cyclin binding and CDK activity (Jeffrey et al, 1995; Paulovich & 
Hartwell, 1995). Activation of CDK4 requires phosphorylation of threonine 172, activation of 
CDK2 requires phosphorylation of threonine 160, and activation of CDK1 requires 
phosphorylation of threonine 161 by the CDK7-cyclin H complex, CAK [reviewed in 
(Vermeulen et al, 2003)]. Alternatively, phosphorylation of cyclin-CDK complexes can also 
inhibit CDK activity when the cyclin-CDK complex is primed by cyclin binding to its 
partner CDK, but the cell does not yet require full activation of the CDK. For example, the 
cyclin A-CDK1 complex can be inhibited by phosphorylation at tyrosine 15 and/or 
threonine 14 by the kinases Wee1 and Myt1. The inhibitory phosphate can be removed by 
the Cdc25 phosphatase; this dephosphorylation is required for the full activation of CDK1 
and subsequent progression through the cell cycle (Lew & Kornbluth, 1996). Once fully 
activated, the CDKs induce downstream signaling events by phosphorylating select 
substrates that regulate cell cycle progression (Morgan, 1997; Pines & Hunter, 1991). One 
such event is the phosphorylation of the retinoblastoma tumor suppressor gene (Rb) by the 
CDK4/6-cyclin D complex. In its active, dephosphorylated state, Rb is in a complex with the 
histone deacetylase protein HDAC and the transcription factors E2F-1 and DP-1. Upon 
phosphorylation in G1 phase, Rb is inactivated, resulting in the release of E2F-1 and DP-1, 
which then activate transcription of genes which are required for S phase progression, 
including those encoding cyclin E, cyclin A, and Cdc25 (Brehm et al, 1998; Buchkovich et al, 
1989; Kato et al, 1993). Rb remains hyperphosphorylated for the remainder of the cell cycle; 
the cyclin E-CDK2 complex stabilizes this hyperphosphorylated state. The cyclin E-CDK2 
complex can also phosphorylate its negative regulator p27, resulting in proteasomal 
degradation of p27 (Hinds et al, 1992; Montagnoli et al, 1999). 
4.1.2 Negative regulators of cell cycle progression: CDK inhibitors 
CDK activity can also be negatively regulated by interaction with various cellular proteins 
that are generically named CDK inhibitors, or CKIs. CKIs can bind to isolated CDKs or to 
the CDK-cyclin complex to prevent the full activation of CDKs [reviewed in (Harper & 
Brooks, 2005)]. There are two families of CKIs, the INK4 (inhibitor of CDK4) family and the 
Cip (CDK-interacting protein)/Kip (kinase inhibitor protein) family [reviewed in (Sherr & 
Roberts, 1995)]. The INK4 family includes p15 (INK4b), p16 (INK4a), p18 (INK4c), and p19 
(INK4d) [reviewed in (Carnero & Hannon, 1998)]. Members of the INK4 family inactivate 
CDK4 and CDK6 by forming stable complexes with the CDK prior to cyclin binding; this 
blocks association of CDK4 and CDK6 with cyclin D and prevents entry into G1 phase 
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[reviewed in (Harper & Brooks, 2005)]. Members of the Cip/Kip family include p21 (Waf1, 
Cip1), p27 (Cip2), and p57 (Kip2); these proteins contain a conserved region that is involved in 
cyclin binding and kinase inhibition [(Polyak et al, 1994a; Polyak et al, 1994b); reviewed in 
(Harper & Brooks, 2005; Roberts et al, 1994)]. Unlike members of the INK4 family, members of 
the Cip/Kip family bind to and inhibit the activity of the entire cyclin-CDK complex. 
Additionally, this CKI family displays a broader specificity than the INK4 family, as its 
members can bind and inhibit the activities of many cyclin-CDK complexes, including cyclin 
E-CDK2, cyclin A- CDK2, and cyclin B-CDK1 [(Hengst et al, 1998; Hengst & Reed, 1998); 
reviewed in (Harper & Brooks, 2005)]. Interestingly, the Cip/Kip family of CKI proteins can 
coordinate the assembly of the cyclin D-CDK4/6 complexes in the early G1 phase and stabilize 
this complex throughout G1 [(Cheng et al, 1999); reviewed in (Sherr & Roberts, 1999)].  
4.2 The cell cycle and HCC 
Deregulation of the cell cycle and alteration in the expression of cyclins and the activities of 
CDKs are frequently observed in transformed cells; consequently, disruption of normal 
mechanisms that regulate the cell cycle is thought to contribute to the development of many 
cancers [reviewed in (Hanahan & Weinberg, 2000)]. The expression of many cell cycle 
regulatory proteins is altered during the onset of HCC and is continually deregulated 
throughout the progression of liver cancer. For example, the transcription promoters of the p15 
and p16 genes are frequently hypermethylated (Csepregi et al, 2010; Matsuda et al, 1999; Shim 
et al, 2003a; Shim et al, 2003b; Wong et al, 2000a; Wong et al, 2000b) and a significant 
percentage of HCCs are associated with decreased expression of p16, which occurs via 
hypermethylation, deletion, or mutation of the p16 gene (Biden et al, 1997; Chaubert et al, 1997; 
Csepregi et al, 2010; Hui et al, 1996; Liew et al, 1999; Matsuda et al, 1999; Shen et al, 1998). 
Expression of DNA methyltransferase I, which methylates the p16 promoter to inhibit 
transcription, is frequently upregulated in HCC (Huang et al, 2010; Oh et al, 2007). Decreased 
expression of p18, a potential tumor suppressor, is associated with poorly differentiated HCCs 
(Morishita et al, 2004). Interestingly, an increase in the phosphorylation of Rb has also been 
observed in HCCs that were negative for p18 expression (Morishita et al, 2004). Rb, a known 
tumor suppressor, is frequently inactivated (hyperphosphorylated) in HCC; approximately 15-
30% of advanced HCCs display mutations in Rb [reviewed in (Burkhart & Sage, 2008)]. In 
addition to alterations in the INK4 family of CKIs, variations in the expression levels of the 
Cip/Kip family have also been found in HCC. Although a number of studies have 
demonstrated that the downregulation of p21 and p27 occurs in HCC, some other reports have 
suggested that the expression of p21 and p27 is increased in HCC (Gramantieri et al, 2003; Qin 
& Ng, 2001; Ren, 1991). Overexpression of cyclin D1 in mice has been linked to the 
development of hyperplasia and ultimately liver cancer (Deane et al, 2001). Importantly, the 
tumor suppressor p53 is frequently lost or mutated in many cancers, including in liver tumors 
[reviewed in (Hollstein et al, 1991)]. It is possible that p53 mutations could lead to the 
alteration of the cell cycle profile of hepatocytes and contribute to the development of liver 
cancer. Overall, it is evident that alterations in the expression levels or activities of cell cycle 
regulatory proteins and protein complexes could play a major role in hepatocarcinogenesis. 
4.3 HBV replication and the cell cycle  
DNA viruses have evolved different strategies to deregulate cell cycle checkpoint controls 
and modulate cell proliferation pathways. Because many DNA viruses primarily infect 
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differentiated, quiescent cells, it is thought these viruses must induce cells to exit G0 and 
enter the cell cycle to create an environment that generates factors, such as nucleotides, that 
are required for viral replication [reviewed in (Mukherji & Kumar, 2008; Swanton & Jones, 
2001)]. An unfortunate consequence of virus-mediated alterations in normal cell cycle 
control mechanisms is that these viral effects may ultimately generate an environment that 
also favors cell transformation and cancer development [reviewed in (Bouchard & Navas-
Martin, 2011; Mukherji & Kumar, 2008)]. 
HBV replication has been associated with modulation of cell cycle progression, and HBV 
replication has been shown to be cell cycle dependent in certain experimental systems 
[reviewed in (Madden & Slagle, 2001)]. HBV replication in Huh7 cells, a human hepatoma 
cell line, and in primary marmoset hepatocytes, was shown to regulate the cell cycle (Chin et 
al, 2007). Huh7 cells infected with HBV were found to stall in the G2 phase of the cell 
cycle; HBV replication in these cells increased activation of both MAPK and Akt 
pathways. Interestingly, p53, p21, cdc2 and intranuclear cyclin B1 levels were elevated in 
primary marmoset hepatocytes that were infected with HBV, which also suggested 
features consistent with a G2 arrest (Chin et al, 2007). Alternatively, the results of studies 
in HepG2.2.15 cells, human hepatoblastoma HepG2 cells that contain an integrated HBV 
genome and replicating HBV, and Huh7 cells that were transiently transfected with the 
HBV genome showed that expression of the HBV genome caused these cells to progress 
through the G1 phase while inhibiting entry into S phase (Friedrich et al, 2005). The 
results of a different study in HepG2.2.15 cells also showed decreased proliferation of 
HepG2.2.15 cells as compared to HepG2 cells; this study also demonstrated that HBV can 
modulate the expression levels of cell cycle regulatory proteins, which resulted in a G1 
phase arrest (Wang et al, 2011). Cumulatively, it can be concluded that HBV infection can 
influence cell cycle progression; however, the exact consequence of HBV infection on cell 
proliferation pathways is likely influenced by the characteristics of the cell type used for a 
particular study. 
Several studies have analyzed the impact of the cell cycle phase on HBV replication. HBV 
replication in HepG2.2.15 cells varied depending on the phase of the cell cycle. Arresting 
HepG2.2.15 cells in either G1 or G2 resulted in an increase in the levels of HBV DNA and 
mRNA, while cell entry into S phase increased cellular DNA synthesis and decreased levels 
of HBV replication (Huang et al, 2004; Ozer et al, 1996). Studies in liver specimens from 
HBV-infected patients demonstrated that hepatocytes expressing proliferating cell nuclear 
antigen (PCNA), which is expressed during S phase and required for DNA replication 
[reviewed in (Harper & Brooks, 2005)], contained negligible amounts of HBV-specific DNA 
(Ozer et al, 1996). Cumulatively, the results of these studies suggest that HBV replication is 
decreased when cells are actively proliferating. The results from a recent study suggested, 
although did not definitively show, that microRNA (miRNA) regulation of cell proliferation 
pathways could affect HBV replication; over-expression of miRNA-1 (miR-1) arrested 
HepG2.2.15 cells in the G1 phase and promoted differentiation, which could be beneficial for 
HBV replication (Zhang et al, 2011). In contrast to studies that demonstrated that HBV 
replication is affected by the phase of the cell cycle, one group demonstrated that HBV 
replication is independent of cell cycle status in HBV-transgenic mice (Guidotti et al, 1997). 
However, because HBV-transgenic mice do not produce cccDNA and do not recapitulate 
every step of an authentic HBV infection, it is unclear whether results in this system 
accurately reflect all mechanisms that can regulate HBV replication (Guidotti et al, 1995). 
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Overall, the results of most studies suggest that cell proliferation pathways are altered in 
cells with replicating HBV and that the status of the cell cycle can influence HBV replication. 
The effect of cell cycle phase on HBV replication in cultured primary rat and human 
hepatocytes will be discussed in a separate section of this chapter. 
4.4 HBx modulation of cell cycle 
HBx expression has been linked to modulation of cell cycle progression, although the effect 
of HBx on cell proliferation pathways has varied depending on the cell type used and the 
experimental conditions of the study [reviewed in (Madden & Slagle, 2001)]. In this section, 
we summarize published studies that have analyzed the impact of HBx on cell cycle 
progression in immortalized or transformed cells; more recent studies in cultured primary 
hepatocytes will be discussed in a separate section. Overall, studies in various immortalized 
or transformed cells have shown that HBx can induce cells to enter the cell cycle, enter the 
cell cycle but stall at G1/S border of the cell cycle, or progress more rapidly through the cell 
cycle (Benn & Schneider, 1994; Benn & Schneider, 1995; Bouchard et al, 2001a; Chen et al, 
2008; Koike et al, 1994; Lee et al, 2002; Mukherji et al, 2007; Singh et al, 2011; Zhang et al, 
2005). It is likely that the observed variations in HBx effects reflect the use of different cell 
lines, different methods of HBx expression, and whether or not the studies were performed 
in the presence of growth factors. It is important to note that some seemingly discrepant 
results that have been reported may reflect a different interpretation of similar data. For 
example, HBx expression can cause cells in G0 to exit G0 but stall at the G1/S phase; this 
could be interpreted as stimulation of cell progression beyond G0 or inhibition of cell 
progression into S phase [reviewed in (Bouchard & Schneider, 2004)]. Additionally, most of 
the studies that analyzed the impact of HBx on cell cycle proliferation and cell cycle 
regulatory proteins were conducted when HBx was expressed in the absence of other HBV 
proteins, and it is unclear whether all the reported HBx activities that were associated with 
regulation of cell proliferation pathways are also present in the context of HBV replication. 
Serum deprivation of cultured cells is a commonly used method for arresting cells in G0 or 
at the G0-G1 junction. When serum-starved Chang liver cells were infected with HBx-
expressing recombinant adenoviruses, HBx increased cellular DNA synthesis and 
stimulated cell proliferation (Benn & Schneider, 1994). HBx eliminated the requirement for 
serum in cell cycle activation in Chang cells, and HBx-expressing Chang cells that were 
stimulated with serum entered S phase and progressed through the G2/M checkpoint more 
rapidly than control cells (Benn & Schneider, 1995). Additionally, HBx activation of Ras was 
necessary for HBx-dependent activation of cell cycling in Chang cells (Benn & Schneider, 
1995). HBx activation of Src kinases was linked with the ability of HBx to cause serum-
starved, quiescent Chang cells to transit through the G1 phase but stall at the G1/S phase of 
the cell cycle (Bouchard et al, 2001a). HBx expression in HepG2 cells increased cellular 
proliferation, as demonstrated in a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) cell proliferation assay (Zhang et al, 2005). Furthermore, an increase in DNA 
synthesis, as demonstrated by bromo-deoxyuridine (BrdU) incorporation, was observed in 
serum starved, HBx-expressing NIH3T3 cells, a mouse embryonic fibroblast cell line (Koike 
et al, 1994). Additional analysis of cell cycle progression in NIH3T3 cells indicated that 
expression of HBx caused cells to move from the G0/G1 phase to the S and G2/M phase 
(Koike et al, 1994). Alternatively, studies in HL-7702 cells, a normal human liver cell line, 
showed that the expression of HBx in these cells caused an increased accumulation of cells 
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in S phase (Chen et al, 2008). The results from another study in Huh7 and human embryonic 
kidney 293 (HEK 293) cells suggested that HBx can cause these cells to transit through the 
G0 and G1/S checkpoints of the cell cycle even in the absence of serum (Mukherji et al, 
2007). Additionally, HBx expression was found to increase the rate of entry of cells into S 
phase, thus causing rapid cycling of these cells; constitutive activation of Src kinases was 
shown to be required for HBx-mediated shortening of the cell cycle (Mukherji et al, 2007). In 
a seminal study that may explain the reason for the different effects of HBx on the cell cycle 
that have been observed in various cellular contexts, HBx expression was shown to 
modulate cell cycle progression differently in cells that had characteristics of differentiated 
or dedifferentiated hepatocytes. In these studies, two HBx-expressing cell lines were derived 
from the same parental AML12 liver cell line. AML12 cells are immortalized mouse 
hepatocytes that were originally derived from TGF-transgenic mice; these cells maintain 
many characteristics that are similar to normal hepatocytes in the liver (Wu et al, 1994a). 
One of the newly derived HBx-expressing AML12 cell lines showed characteristics similar to 
differentiated hepatocytes, whereas the other cell line displayed a more dedifferentiated 
phenotype (Tarn et al, 1999; Wu et al, 1994b). HBx expression in the more differentiated cells 
caused the cells to rapidly progress through the cell cycle; however, HBx expression in the 
more dedifferentiated cells caused these cells to enter the cell cycle but pause in S phase (Lee 
et al, 2002). These observations support the notion that the impact of HBx on cell 
proliferation pathways varies depending on the characteristics of the cells used for the 
study. Taken together, the results of these numerous studies suggest that HBx can modulate 
cell cycle progression, though the exact impact of HBx on cell proliferation pathways when 
HBx is expressed from replicating HBV in normal hepatocytes in the liver remains to be 
completely defined. 
4.4.1 HBx regulation of cyclins and CDKs 
The results of multiple studies have demonstrated that HBx can regulate the levels of cyclins 
and the activities of CDKs, although these HBx activities have varied in different 
experimental conditions. In one study, both stable and transient expression of HBx was 
found to increase the level of cyclin D1 in HepG2 cells (Jung et al, 2007). The level of cyclin 
D1 was also elevated in Huh7 cells that contained replicating HBV; however, this 
observation could not be directly linked to HBx since the effects of HBV on cell cycle 
regulatory proteins was not compared to an HBx-deficient HBV (Chin et al, 2007). Studies 
from another group suggested that HBx activation of NF-B may play a role in up-
regulation of cyclin D1 levels in Chang cells (Park et al, 2006). Additional studies have 
shown that HBx can also regulate the expression levels of cyclins that are required during 
later stages of the cell cycle. HBx activated the cyclin A promoter, increased cyclin A protein 
levels, and promoted the formation of cyclin A-CDK2 complexes in ts13 cells (Bouchard et 
al, 2001a); these cells are derived from a hamster cell line containing a temperature-sensitive 
defect in TBP-associated factor 250 (TAFII 250). The TAFII 250 ts13 mutation has been 
shown to induce cell cycle arrest and apoptosis when these cells are shifted from the 
permissive temperature to the nonpermissive temperature (Hayashida et al, 1994; Talavera 
& Basilico, 1977). The ability of HBx to activate the endogenous cyclin A promoter and 
cyclin A-CDK2 complexes was linked to stimulation of Src kinase signaling pathways 
(Bouchard et al, 2001a). HBV replication in Huh7 cells increased the levels of cyclin A and 
intranuclear cyclin B, which is active during the G2/M phase. Whether the elevation of 
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cyclin A or intranuclear cyclin B was caused by HBx in these studies is not entirely clear 
because the results were not compared to similar assays with an HBx-deficient HBV (Chin et 
al, 2007). HBx increased the activation of CDK2 and CDK1 in Chang liver cells; this HBx 
activity was blocked with a dominant-negative mutant of Ras (Benn & Schneider, 1995). 
Finally, the results of studies in Huh7 cells demonstrated that HBx expression increased the 
stability of cyclin E in these cells and significantly enhanced CDK2 activity (Mukherji et al, 
2007). Moreover, HBx was able to bind to the cyclin E/A-CDK2 complex in Huh 7 cells; 
expression of c-terminal src kinase (CSK), a physiological inhibitor of Src kinases, abrogated 
the interaction of HBx with the cyclin E-CDK2 complex (Mukherji et al, 2007). Overall, the 
various studies in immortalized and transformed cells demonstrate that HBx can modulate 
the levels and activities of positive regulators of the cell cycle. Whether similar HBx 
activities are apparent in the context of an authentic HBV infection of hepatocytes in the 
liver awaits further investigation. 
4.4.2 HBx regulation of CKIs 
In addition to the influence of HBx on positive regulators of the cell cycle, the results of 
some studies have suggested that HBx can also affect negative cell cycle regulators. These 
studies have mainly focused on the effect of HBx expression on the expression levels of p16, 
p21, and p27. Studies in HBV-associated cirrhotic livers and HBV-producing HCC cell lines 
showed a correlation between the hypermethylation of the p16 gene, decreased expression 
of p16, and the presence of HBV (Shim et al, 2003b). Although this study demonstrated that 
HBV replication may be associated with deregulation of p16, these findings were not 
directly linked to HBx expression. However, in a subsequent study in HBV-associated HCC 
liver sections, the methylation status of the p16 promoter was analyzed; liver sections that 
contained high levels of methylated p16 promoters also had high expression levels of HBx, 
indicating that HBx expression correlates with the methylation status of the p16 promoter 
(Zhu et al, 2007). Studies in HepG2 cells stably transfected with an HBx-expression plasmid 
showed that HBx induced hypermethylation of the p16 promoter and down-regulation of 
p16 protein levels, which resulted in the activation of the cyclin D1-CDK4/6 complex, 
phosphorylation of Rb, activation of E2F1, and transcriptional activation of DNA 
methyltransferase 1 (DNMT1) (Jung et al, 2007). Interestingly, this induction of DNMT1 
expression was found to be required for the p16 promoter methylation and also for the 
expression of DNMT1 itself, suggesting that there is communication between p16 and 
DNMT1 (Jung et al, 2007). The results of an additional study demonstrated that the HBx-
mediated reduction in p16 expression enabled HBx-expressing HepG2 cells to evade H2O2-
induced senescence (Kim et al, 2010). Studies in liver tissue samples from HBV-associated 
HCCs and corresponding HBV-infected non-cancerous liver sections showed that in the 
non-cancerous tissues, HBx expression correlated positively with DNMT1 expression and 
negatively with p16 protein expression (Zhu et al, 2010). Alternatively, in the HCC tissues, 
HBx expression still correlated positively with DNMT1 expression, but did not correlate 
with the hypermethylation of the p16 promoter or with p16 expression, suggesting that 
HBx-mediated hypermethylation of p16 may play a role in the early stages of HBV-related 
hepatocarcinogenesis (Zhu et al, 2010). 
The results of various studies have also suggested that HBx can alter the expression of p21 
and p27. In Huh7 cells that were infected with a recombinant HBV-encoding adenovirus, an 
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increase in p21 was observed; however, these findings were not directly linked to HBx 
expression because the results were not compared to Huh7 cells infected with a recombinant 
adenovirus that contained an HBV mutant that lacked HBx expression (Chin et al, 2007). In 
another study in HBx-expressing NIH3T3 cells, a dose-dependent increase in the 
transcription of p21 was observed when p53 was functional (Ahn et al, 2002). Alternatively, 
in the absence or down-regulation of p53, a repression of p21 transcription by HBx was 
observed in NIH3T3 cells (Ahn et al, 2002). Moreover, HBx expression decreased the level of 
p21 RNA in NIH3T3 cells, which may be due to p53-independent transcriptional repression, 
resulting from an HBx-mediated Sp-1 inactivation (Ahn et al, 2001). Sp-1 is a transcription 
factor that can activate transcription of many target genes, including p21 (Pardali et al, 
2000). Transcriptional repression of p21 was also observed in NIH3T3 cells co-transfected 
with plasmids encoding HBx and the hepatitis C virus (HCV) core protein (Han et al, 2002). 
While there have been many studies that have investigated the role of HBx in regulating 
p21, much less is known about the effect of HBx on p27. In Huh7 cells, HBx expression was 
found to increase proteasomal degradation of p27 (Mukherji et al, 2007). Overall, the precise 
impact of HBx expression on members of the Cip/Kip family seems to vary in different 
cellular contexts, and both upregulation and downregulation of the CIP/KIP family has 
been observed. Interestingly, the results of one study showed that the level of HBx 
expression influences its effects on p21 and p27 (Leach et al, 2003). When HBx was 
expressed at low levels in Chinese hamster ovary (CHO) cells, an increased activity of the 
p21 and p27 promoters was observed. Alternatively, when HBx was expressed at high levels 
in CHO cells, there was inhibition of the activity of the p21 and p27 promoters. This study 
suggests that the experimental conditions that are used to study HBx modulation of CKIs 
can influence the observed effect of HBx. 
4.4.3 HBx regulation of cell proliferation in primary hepatocytes 
Although various studies have analyzed the impact of HBx on cell proliferation pathways, 
many of these studies have identified different HBx effects. Most of these studies were 
conducted in transformed or immortalized cell lines and when HBx was overexpressed in 
the absence of other HBV proteins, which could contribute to the different HBx activities 
that were observed. Because established cell lines often contain changes in pathways that 
control normal cell cycle progression, observations of HBx activities in these cells could 
reflect HBx activities that are apparent in a specific context but not necessarily present in 
normal hepatocytes during an HBV infection. Recent studies in cultured primary 
hepatocytes have begun to address the effect of HBx expression, both on its own and when 
expressed in the context of replicating HBV, on hepatocyte cell cycle regulatory pathways. 
These studies have provided important insights into HBx activities that regulate HBV 
replication and could influence the development of HBV associated HCC. 
Cultured primary rat hepatocytes are a biologically relevant model system that can be used 
to characterize HBx activities in normal, untransformed hepatocytes. In a series of studies in 
cultured primary rat hepatocytes, the impact of HBx on cell cycle regulation and HBV 
replication in normal hepatocytes was analyzed (Figure 3). In cultured primary rat 
hepatocytes, HBx decreased the expression level of both p15 and p16 while increasing the 
expression of p21 and p27, demonstrating that HBx decreased the levels of factors that 
maintained the quiescent status of hepatocytes and elevated the levels of inhibitors of cell  
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Fig. 3. Summary of HBx effects on the cell cycle in cultured primary hepatocytes. See text for 
details. 
cycle progression past late G1 phase (Gearhart & Bouchard, 2010a). Similar studies in 
primary mouse hepatocytes that were infected with a recombinant HBx-expressing 
adenovirus also showed that HBx increased expression of both p21 and p27 and decreased 
DNA synthesis (Qiao et al, 2001). Finally, another study also identified an increase in p21 
protein levels in primary mouse hepatocytes infected with a recombinant HBV-expressing 
adenovirus; however, these results were not directly linked to HBx expression because they 
were not compared to similar studies with an HBx-deficient HBV (Chin et al, 2007). In 
cultured primary rat hepatocytes, an increase in cyclin D1 and cyclin E expression in the 
presence of HBx was also observed; however, HBx-induced changes in S phase activating 
proteins, such as cyclin A and PCNA, were not observed, indicating that HBx expression 
did not cause entry into S phase (Gearhart & Bouchard, 2010a). Importantly, similar HBx 
activities were observed in cultured primary human hepatocytes that were infected with a 
recombinant HBx-expressing adenovirus (Gearhart & Bouchard, 2011) and in cultured 
primary rat hepatocytes infected with recombinant adenoviruses encoding the full HBV 
genome that was compared to a mutant HBV that did not produce HBx (Gearhart & 
Bouchard, 2010a). To determine the significance of the HBx-mediated elevation of cyclin D1 
and cyclin E protein levels, the effect of HBx on the activities of CDK4 and CDK2 in cultured 
primary rat hepatocytes was also examined (Gearhart & Bouchard, 2010a). CDK4 and CDK2 
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activities were analyzed using standard kinase assays; the substrate for CDK4 
phosphorylation was Rb and the substrate for CDK2 phosphorylation was histone H1. To 
analyze CDK2 activity, primary rat hepatocytes were plated at 50% confluency and 
stimulated with hepatocyte growth factor (HGF) to induce proliferation (Gearhart & 
Bouchard, 2010a). HBx, expressed either alone or in the context of HBV replication, 
increased the activity of CDK4 but decreased the activity of CDK2 (Gearhart & Bouchard, 
2010a). The results of these studies confirmed that the HBx-mediated increase in cyclin D1 
correlated with increased CDK4 activity; however, the increase in cyclin E expression was 
not coupled to an increase in CDK2 activity, confirming that HBx prevents cell cycle 
progression past G1 phase in normal hepatocytes. It is likely that HBx elevation of p21 and 
p27 inhibits the activity of cyclinE-CDK2 complexes. In contrast, the CIP/KIP proteins are 
thought to stimulate cell cycle progression in early G1 phase, which may contribute to the 
ability of HBx to cause hepatocytes to exit G0 and enter G1 [(Cheng et al, 1999); reviewed in 
(Harper & Brooks, 2005; Sherr & Roberts, 1999)]. Overall, these studies suggest that HBx 
causes quiescent hepatocytes to exit G0 but stall in G1. 
Studies in primary rat hepatocytes were also conducted to examine the effect of cell cycle 
progression on HBV replication. Downregulation of p16 is required for cells to exit 
quiescence and enter the cell cycle [reviewed in (Harper & Brooks, 2005)]; primary rat 
hepatocytes were transfected with a p16 overexpression plasmid, infected with an HBV-
encoding recombinant adenovirus, and HBV replication was analyzed to determine if HBV 
replication requires quiescent hepatocytes to enter the cell cycle (Gearhart & Bouchard, 
2010a). Interestingly, preventing hepatocytes from entering the cell cycle by the 
overexpression of p16, inhibited HBV replication (Gearhart & Bouchard, 2010a). 
Importantly, this study was the first to directly examine the effect of cell quiescence on HBV 
replication and indicated that the HBx-mediated exit from quiescence is critical for HBV 
replication in normal hepatocytes. While this study was consistent with previous reports 
which indicate that HBV replication is higher in G1 phase (Huang et al, 2004; Ozer et al, 
1996), it is important to note that some studies indicate that HBV may replicate better in 
quiescent cells (Friedrich et al, 2005; Guidotti et al, 1997); however, in contrast to the 
described studies in cultured primary rat hepatocytes, the studies that suggested that HBV 
replicates better in quiescent cells did not distinguish between the G0 and G1 phase of the 
cell cycle. Studies in primary rat hepatocytes were also conducted to determine whether the 
HBx-mediated cell cycle arrest at the G1/S phase border was also required for HBV 
replication. When levels of HBV replication were measured in cultured primary rat 
hepatocytes that were transfected with siRNAs to decrease expression of p21, p27, or both 
p21 and p27, replication levels were considerably lower when both p21 and p27 levels were 
decreased, as compared to control samples or samples in which p21 or p27 levels were 
individually decreased (Gearhart & Bouchard, 2010b). Overall, the results of these studies 
showed that HBV replication in cultured primary rat hepatocytes is regulated by HBx-
mediated G1 entry from G0 and cell cycle arrest at the G1/S phase border; HBV replication 
is inhibited when hepatocytes are in S phase.  
Finally, to determine how HBx-mediated modulation of the cell cycle affects HBV 
replication, studies in cultured primary rat hepatocytes were conducted to define how cell 
cycle modulation influences the activity of the HBV reverse transcriptase/polymerase. The 
activity of the HBV polymerase was assessed in hepatocytes that were infected with 
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recombinant HBV-expressing adenoviruses and transfected with a p16 overexpression 
plasmid or siRNAs to p21 or p27 or both p21 and p27 (Gearhart & Bouchard, 2010b). The 
results of these studies demonstrated that entry of quiescent, primary rat hepatocytes into 
the G1 phase of the cell cycle is required for the activation of the HBV polymerase while 
progression into S phase did not affect the activity of the HBV polymerase (Gearhart & 
Bouchard, 2010b). In contrast, progression into S phase may inhibit HBV replication by 
causing a competition between the cell and the HBV replication machinery for available 
deoxynucleotide triphosphates (dNTPs). The levels of dNTPs in quiescent cells is low, and 
HBx modulation of the cell cycle is thought to increase the levels of cellular dNTPs that are 
available to the HBV polymerase [reviewed in (Yamashita & Emerman, 2006)]. 
Ribonucleotide reductase is the rate-limiting enzyme of DNA synthesis and is responsible 
for the synthesis of dNTPs [reviewed in (Elledge et al, 1992; Reichard, 1987)]. This enzyme 
contains two subunits, R1 and R2; R1 is expressed constitutively; however, the synthesis of 
R2, the catalytic subunit of ribonucleotide reductase, peaks closer to S phase, when the cells 
prepare for replication (Chabes & Thelander, 2000). Interestingly, HBx expression increased 
the levels of R2 in cultured primary rat and human hepatocytes, which would lead to the 
activation of ribonucleotide reductase and a possible increase in the number of available 
dNTPs (Gearhart & Bouchard, 2010b; Gearhart & Bouchard, 2011). Additional studies 
demonstrated that HBx elevation of R2 is required for HBV replication in cultured primary 
rat hepatocytes. Hydroxyurea, an inhibitor of ribonucleotide reductase (Thelander & 
Reichard, 1979), blocked HBV replication, as did transfection of a siRNA that targeted R2 
(Gearhart & Bouchard, 2010b). Importantly, both hydroxyurea and the siRNA targeting R2 
did not affect the activity of the HBV polymerase (Gearhart & Bouchard, 2010b). 
Cumulatively, the studies in primary hepatocytes demonstrated that HBx stimulates HBV 
replication by inducing hepatocytes to exit G0 and enter G1 to activate the HBV polymerase 
and increase the level of the R2 subunit of ribonucleotide reductase. Additionally, these 
studies confirmed that cultured rodent hepatocytes can serve as a powerful model system 
for studying HBx activities that are present in normal human hepatocytes, which are not 
always readily available for similar types of studies. Since deregulation of cell cycle 
checkpoints have been linked to cancer development [reviewed in (Collins et al, 1997; Ford 
& Pardee, 1999)], HBx modulation of cell cycle proliferation might also contribute to 
processes that influence the development of HBV-associated liver transformation by 
stimulating HBV replication and altering normal cell cycle control mechanisms in 
hepatocytes (Gearhart & Bouchard, 2010b). Overall, these observations indicate that HBx 
regulates the expression of cell cycle regulatory factors in normal hepatocytes when it is 
expressed in the absence of other HBV proteins and in the context of replication.  
4.4.4 HBx and liver regeneration 
Several studies have examined the effect of HBx expression on liver regeneration. In one 
study, moderate expression levels of HBx resulted in an inhibition of liver regeneration 
following a partial hepatectomy in HBx-transgenic mice (Tralhao et al, 2002). Overall 
inhibition of liver regeneration was also observed after a partial hepatectomy in mice that 
were transplanted with HBx-expressing liver cells (Tralhao et al, 2002). HBx-mediated 
inhibition of liver regeneration in HBx-transgenic mice occurred at the G1/S phase 
transition (Wu et al, 2006). HBx also caused an increase in the levels of alanine 
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aminotransferase and alpha-fetoprotein (AFP) that were detected after the partial 
hepatectomy, indicating that HBx expression made the hepatocytes more susceptible to 
damage during regeneration (Wu et al, 2006). HBx also caused abnormal apoptosis, fat 
accumulation, and impaired glycogen storage when HBx was expressed during periods of 
regeneration (Wu et al, 2006). In contrast, the results of one study suggested that HBx can 
increase cell cycle progression following a partial hepatectomy in HBx-transgenic mice; in 
this study the effect of HBx on regeneration was measured by BrdU incorporation, levels of 
PCNA, and reduced steady-state p21 protein levels (Hodgson et al, 2008). Finally, in another 
study in HBx-transgenic mice, hepatocytes in these mice had both increased proliferation 
capacity and increased apoptosis; whether increased hepatocyte proliferation was induced 
to compensate for the increased apoptosis, or whether increased apoptosis was in response 
to the increased hepatocyte proliferation was not directly addressed (Koike et al, 1998). 
Overall, these studies indicate that HBx can modulate liver regeneration; however, due to 
differences in the mouse strains and methods of analysis that were used to address the 
influence of HBx expression on liver regeneration, the exact impact of HBx on liver 
regeneration is not fully understood but could be a major contributor to the development of 
HBV-associated HCC. 
4.5 HBx and calcium signaling 
4.5.1 Calcium signaling overview 
Calcium (Ca2+) signaling controls a diverse range of cellular processes including cell 
proliferation, signal transduction, transcription, and apoptotic pathways [reviewed in 
(Berridge et al, 2003; Berridge et al, 2000; Bootman et al, 2001; Parekh, 2011)]. Calcium 
signals typically take the form of oscillating calcium spikes, and differences in the 
amplitude, frequency and spatial patterns of calcium oscillations will initiate different 
cellular responses, leading to a paradoxical combination of specificity and versatility in 
calcium signaling [reviewed in (Berridge et al, 2003; Berridge et al, 2000; Bootman et al, 
2001; Parekh, 2011)]. The signaling functions of Ca2+ mainly depend on the calcium 
concentration in the cytosolic compartment. The cytosolic calcium level ([Ca2+]c) in most 
resting cells is maintained at around 100nM but can reach 1000nM upon stimulation 
[reviewed in (Berridge et al, 2000)]. The [Ca2+]c is regulated by the dynamic interplay 
between calcium “ON” and “OFF” mechanisms that can increase or decrease  [Ca2+]c 
[reviewed in (Berridge et al, 2003; Berridge et al, 2000; Bootman et al, 2001)]. 
The calcium “ON” mechanism includes external calcium entry and internal calcium release 
from the endoplasmic reticulum (ER) [reviewed in (Berridge et al, 2003; Berridge et al, 2000; 
Bootman et al, 2001)]. A variety of plasma membrane calcium channels responsible for 
external calcium entry have been identified, including voltage-operated calcium (VOC) 
channels, receptor-operated calcium (ROC) channels, and store-operated calcium (SOC) 
channels [reviewed in (Berridge et al, 2003; Berridge et al, 2000; Bootman et al, 2001)]. The 
ER is the main internal calcium store, and inositol 1,4,5-triphosphate receptors (IP3R) and 
ryanodine receptors (RyR) are the best-characterized ER calcium-releasing channels 
[reviewed in (Berridge et al, 2003; Berridge et al, 2000; Bootman et al, 2001)]. In non-excitable 
cells, such as hepatocytes, cytosolic calcium signals mainly derive from ER calcium release. 
Extracellular agonists such as hormones or growth factors activate phospholipase C through 
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plasma membrane associated G-protein-coupled receptors or receptor tyrosine kinases, 
resulting in the breakdown of phosphatidylinositol 4,5-bisphoshate to produce inositol 1,4,5-
triphosphate (IP3). IP3 binds to IP3Rs on the ER membrane and stimulates calcium release 
from the ER [reviewed in (Berridge, 1993; Berridge, 2009)]. IP3-linked ER calcium release is 
followed by extracellular calcium influx to replenish the ER calcium store, which is referred 
to as store-operated calcium entry (SOCE) (Putney, 1986). SOCE is essential for maintaining 
IP3-induced cytosolic calcium oscillations and normal ER functions, and also helps sustain 
elevated levels of  [Ca2+]c [reviewed in (Burdakov et al, 2005; Putney & Bird, 2008; Smyth et 
al, 2006)]. The process of SOCE is mediated by SOC channels, and the best characterized 
SOC channel is the calcium-release-activated calcium (CRAC) channel, which is highly 
selective for calcium and only activated by ER calcium depletion [reviewed in (Parekh, 
2010)]. Recently, the ER transmembrane stromal interaction molecule (Stim) 1 (Stim1) and 
the plasma membrane proteins Orai family (Orai1, 2, and 3) have been identified as key 
molecular components of mammalian CRAC channels [reviewed in (Parekh, 2010)]. 
Once calcium signals are generated by the calcium “ON” mechanisms, they will be 
decoded and translated into different cellular processes by numerous calcium sensors. 
Some of these sensors, such as protein kinase C, bind to Ca2+ and are directly regulated in 
a Ca2+-dependent manner. Other calcium sensors, such as calmodulin (CaM), act as 
intermediaries to couple calcium signals with distal targets and specific cellular responses. 
CaM is a versatile calcium sensor with two C-terminal and two N-terminal EF-hand Ca2+-
binding motifs; these motifs bind Ca2+ and induce conformational changes in CaM that 
facilitate activation of various downstream effectors, including CaM kinases (CaMKs) and 
calcineurin [reviewed in (Berridge et al, 2000; Parekh, 2011)]. Calcium signals also 
communicate with other signaling molecules including cyclic AMP, nitric oxide, 
phosphatidylinositol-3-OH (PI3) kinase, and MAPK [reviewed in (Berridge et al, 2000)]. 
Communication between calcium signaling and other signaling pathways greatly 
enhances the diverse functions of a calcium signal.  
After a calcium signal has been executed, excess calcium will be rapidly removed from the 
cytosol by calcium pumps and exchangers; these pumps and exchangers constitute the 
cellular calcium “OFF” mechanisms [reviewed in (Berridge et al, 2000)]. The plasma 
membrane Ca2+-ATPase pumps (PMCA) and Na+/Ca2+ exchangers can remove Ca2+ from 
the cytosol and transport Ca2+ to the extracellular environment. The sarco-endoplasmic 
reticulum ATPase (SERCA) pumps can pump Ca2+ from the cytosol into the ER (Berridge et 
al, 2003; Berridge et al, 2000; Bootman et al, 2001). Mitochondria also function as an 
important “OFF” mechanism by rapidly sequestering cytosolic Ca2+ during the rising phase 
of Ca2+ signals and then slowly releasing the Ca2+ back into the cytosol during the declining 
phase of Ca2+ signals (Berridge et al, 2000). Mitochondrial Ca2+ transport can buffer a 
harmful elevation of cytosolic Ca2+ and also increase the duration of Ca2+ signals in the 
cytosol. Mitochondria, therefore, have an important role in shaping both the amplitude and 
spatio-temporal patterns of Ca2+ signals [reviewed in (Berridge et al, 2000; Bootman et al, 
2001)]. The major mitochondrial Ca2+ uptake mechanism is the mitochondrial Ca2+ uniporter 
(MCU) [reviewed in (Bernardi, 1999)]. Although the MCU has low Ca2+ affinity, a local high 
Ca2+ concentration in the ER-mitochondria microdomain can overcome this limitation and 
facilitate rapid mitochondrial Ca2+ uptake from the cytosol through the MCU during IP3-
linked Ca2+ signaling (Rizzuto et al, 1993; Rizzuto et al, 1998). Mitochondrial Ca2+ efflux 
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mechanisms mainly include the mitochondrial Na+/Ca2+ exchanger and the MPTP; the 
MPTP is a mitochondrial protein complex that is thought to be composed of VDAC, the 
adenine nucleotide translocase (ANT) and cyclophilin D (CypD) [reviewed in (Bernardi, 
1999)]. The MPTP has two conductance states: at the low conductance state, the MPTP can 
function as a mitochondrial Ca2+ efflux channel; at an irreversible high conductance state, 
mitochondria permeability transition will be induced and lead to the release of cytochrome 
C and the initiation of apoptosis (Ichas et al, 1997; Zoratti & Szabo, 1995). 
4.5.2 Calcium signaling and the cell cycle 
It is well recognized that Ca2+ signaling is involved at different stages of the cell cycle, 
especially during the early G1 phase as well as at the G1/S and G2/M transitions. Both 
extracellular Ca2+ and intracellular Ca2+ are required for cell proliferation. In one study, 
when the extracellular Ca2+ concentration was reduced from 1mM to 0.1mM, the rate of cell 
proliferation was gradually decreased (Hickie et al, 1983). The results of another study 
demonstrated that when intracellular Ca2+ stores were depleted with pharmacological 
agents, cell division was also blocked (Short et al, 1993). The role of Ca2+ signaling in 
progression through G1 and the G1/S boundary is particularly important. Ca2+ spikes have 
been observed in early G1 and near the G1/S boundary in cells [reviewed in (Kahl & Means, 
2003)]. During the G1 phase, Ca2+ affects the expression of cyclin D1 by regulating the 
expression or activity of transcription factors such as fos, jun, and myc [reviewed in 
(Roderick & Cook, 2008)]; Ca2+ signals can also stimulate phosphorylation of Rb at the G1/S 
boundary (Takuwa et al, 1993).  
CaM is a general Ca2+ sensor and relays Ca2+ signals to Ca2+/CaM-dependent targets. The 
expression level of CaM is regulated during cell cycle progression, and a pronounced 
increase in CaM levels just before entering S phase has been observed in different cell types 
[reviewed in (Kahl & Means, 2003)]. Increased CaM levels accelerated the rate at which cells 
passed through the G1/S boundary, and a decrease in CaM levels prevented progression 
into S phase, indicating that CaM can control the rate of entering into S phase (Rasmussen & 
Means, 1989). The addition of CaM inhibitors early in the G1 phase could completely inhibit 
DNA synthesis, but CaM inhibitors did not affect DNA synthesis if the inhibitors were 
added later in G1 after Rb hyperphosphorylation, suggesting that the requirement for 
Ca2+/CaM in late G1 phase is before Rb hyperphosphorylation (Takuwa et al, 1992; Takuwa 
et al, 1993). Although the detailed molecular mechanisms that underlie these Ca2+/CaM 
effects remain unknown, it is evident that Ca2+ signaling can affect multiple signaling 
pathways to regulate G1 progression. 
Two Ca2+/CaM-dependent targets, calcineurin and CaMKs, have been shown to play an 
important role in cell-cycle progression and cell proliferation [reviewed in (Kahl & Means, 
2003)]. The multifunctional CaMKs are a family of serine/threonine protein kinases that 
includes CaMKI, CaMKII, and CaMKIV. The auto-inhibition of CaMKs is removed upon the 
binding of Ca2+/CaM, which stimulates CaMK kinase activity [reviewed in (Kahl & Means, 
2003)]. CaMKs are also associated with different aspects of cell cycle progression. In both 
normal and transformed cells, inhibition of CaMKs prevented G1 progression, suggesting 
that CaMKs are required for G1 progression [reviewed in (Kahl & Means, 2003)]. In vitro, 
CaMKI and CaMKII phosphorylated and increased the activity of cdc25C, a phosphatase 
responsible for cdc2 activation at the G2/M transition (Patel et al, 1999). Calcineurin is a 
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Ca2+/CaM-dependent phosphatase, and its enzyme activity is stimulated by binding of 
Ca2+/CaM to its regulatory domain [reviewed in (Kahl & Means, 2003)]. Calcineurin can 
affect cyclin D1 expression and control G1 progression by regulating cAMP-responsive 
element binding protein (CREB), which binds to the cyclin D1 promoter (Schneider et al, 
2002). NFAT activation by calcineurin can also induce the expression of c-myc and increase 
the expression of E2F and cyclin E  [reviewed in (Roderick & Cook, 2008)]. Finally, inhibition 
of calcineurin suppresses CDK2 activity because of increased expression of p21 or reduced 
cyclin E levels (Khanna & Hosenpud, 1999; Tomono et al, 1998). 
Because of the pivotal role of calcium signaling in cell proliferation, abnormal Ca2+ signaling 
may contribute to the development of cancer [reviewed in (Parkash & Asotra, 2010; 
Roderick & Cook, 2008)]. The involvement of Ca2+, CaM, calcineurin, and NFAT signaling in 
carcinogenesis has been implicated in many different human malignant tumors. NFAT-
mediated signaling can affect the development of cancer by upregulation of VEGF to 
stimulate angiogenesis, by upregulation of c-Myc to prompt tumor cell proliferation, and by 
upregulation of Cox-2 to facilitate tumor cell migration (Buchholz & Ellenrieder, 2007). Ca2+ 
signaling can also regulate oncogenic signaling pathways by contributing to the magnitude 
and duration of Ras and ERK activation [reviewed in (Roderick & Cook, 2008)]. 
Furthermore, deregulation of Ca2+ signals that are involved in centrosome replication and 
separation can result in aberrant mitotic spindles and genetic instability, contributing to the 
development of cancer [reviewed in (Roderick & Cook, 2008)]. Taken together, remodeling 
of Ca2+ signaling in cell proliferation may act as an oncogenic mechanism facilitating the 
development of cancer. 
4.5.3 HBx modulation of the cell cycle requires calcium signaling 
Various studies suggest that HBx modulates cytosolic Ca2+ signaling, which likely acts as an 
initiator of other reported HBx activities (Bouchard et al, 2006; Bouchard et al, 2001b; 
Gearhart & Bouchard, 2010a; Gearhart & Bouchard, 2010b). This notion is supported by 
studies of regulation of cell cycle and cell proliferation in cultured primary rat hepatocytes 
(Gearhart & Bouchard, 2010a; Gearhart & Bouchard, 2010b). Studies in cultured primary rat 
hepatocytes have demonstrated that HBx induced quiescent hepatocytes to enter the G1 
phase of cell cycle but not to proceed to S phase and that HBV replication was reduced 
when cultured primary rat hepatocytes entry into G1 phase was blocked or when cultured 
primary rat hepatocytes entered S phase (Gearhart & Bouchard, 2010a; Gearhart & 
Bouchard, 2010b). Of significance to the role of HBx modulation of Ca2+ signals, these 
studies in cultured primary rat hepatocytes showed that treatment with BAPTA-AM, an 
intracellular Ca2+ chelator, inhibited HBx modulation of cell cycle regulatory proteins and 
abolished HBV replication, suggesting that HBx regulation of cell proliferation to stimulate 
HBV replication requires Ca2+ signaling (Gearhart & Bouchard, 2010a; Gearhart & 
Bouchard, 2010b). This conclusion is consistent with previous studies in HepG2 cells that 
showed that the modulation of Ca2+ signaling by HBx is essential to stimulate HBV 
replication. In HepG2 cells, the replication of HBx-deficient HBV was significantly 
reduced and was rescued by co-transfecting with an HBx-expressing plasmid or by 
simply increasing cytosolic Ca2+ levels; BAPTA-AM treatment inhibited HBV replication 
(Bouchard et al, 2001b). Furthermore, the activation of Pyk2/FAK and Src kinase pathway 
has been identified as one of the downstream pathways of HBx-regulated Ca2+ signals that 
stimulates HBV replication in HepG2 cells. HBx activation of Pyk2/FAK and Src kinases 
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was Ca2+-dependent, and the inhibition of Pyk2/FAK and Src kinases blocked HBx-
stimulated HBV replication in HepG2 cells (Bouchard et al, 2003; Bouchard et al, 2006; 
Bouchard et al, 2001b). Taken together, these studies suggest that HBx modulation of Ca2+ 
signaling can stimulate HBV replication in both HepG2 cells and cultured primary rat 
hepatocytes. In addition, these studies show that HBx regulation of hepatocyte 
proliferation is directly linked to HBx stimulation of Ca2+ signals. 
An unanswered question is precisely how HBx modulates cellular Ca2+ signals. The results 
of many studies suggest that HBx affects Ca2+ signaling by regulating the MPTP. Because 
cyclosporin A (CsA) inhibits both the MPTP and calcineurin and FK506 is only a calcineurin 
inhibitor that does not affect MPTP, the combined use of these two inhibitors has helped to 
define whether MPTP is involved in a specific cellular process. Importantly, CsA treatment, 
but not FK506 exposure, blocked the effect of HBx on cell cycle regulatory proteins such as 
p15, p16, p21, and p27 and HBx stimulation of HBV replication in cultured primary rat 
hepatocytes, indicating that HBx modulation of cell cycle factors in cultured primary rat 
hepatocytes is MPTP-dependent (Gearhart & Bouchard, 2010b). Similar results were 
observed in HepG2 cells that were treated with CsA; CsA treatment blocked HBx 
stimulation of HBV replication and activation of Pyk2 and FAK (Bouchard et al, 2006; 
Bouchard et al, 2001b). Finally, the direct link between HBx modulation of Ca2+ signaling   
 
Fig. 4. HBx modulation of cell cycle in primary hepatocytes may lead to the development of 
HCC. Refer to Figure 2 for the other activities of HBx that could play a potential role in the 
development of HBV-induced HCC. See text and references for details. 
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and the MPTP was established in HepG2 cells. In these cells, HBx, both by itself and in the 
context of HBV replication, increased the basal cytosolic Ca2+ level; this increase was 
blocked by CsA treatment, suggesting that MPTP is involved in the regulation of cytosolic 
calcium signals (McClain et al, 2007). Cumulatively, these studies suggest that HBx affects 
cellular Ca2+ signaling in a manner that is dependent on the MPTP. Whether CaM acts a 
mediator of HBx-induced calcium signals remains to be investigated. Remodeling of Ca2+ 
signals and the impact of this on cell proliferation could contribute to carcinogenesis, and 
HBx modulation of cellular Ca2+ signals may contribute to the development of HBV-
associated HCC. The precise mechanism used by HBx to regulate cellular Ca2+ signals 
through the MPTP remains unclear, and a better understanding of this HBx activity may 
provide new targets for treatment of chronic HBV infections and prevention of the 
development of HBV-associated HCC. 
4.6 Conclusions and future directions 
4.6.1 HBx modulation of calcium signaling and the cell cycle in hepatocarcinogenesis 
HBx can influence a number of cellular activities that could alter normal hepatocyte 
physiology and predispose hepatocytes to transformation; these activities may include HBx 
regulation of cellular signal transduction, transcription, proliferation, and apoptotic 
pathways, as well as the direct interaction of HBx with cellular proteins such as UV-DDB 
and p53. In this chapter,  we have focused on HBx modulation of hepatocyte proliferation 
pathways and cellular calcium signaling as HBx activities that could be major contributing 
factors to the development of HBV-associated HCC (Figure 4). Deregulation of calcium 
signaling can alter normal cellular physiology, thus potentially contributing to cancer 
development [reviewed in (Parkash & Asotra, 2010)]. As the upstream mediator of many 
HBx effects (Bouchard et al, 2006; Bouchard et al, 2001b; Gearhart & Bouchard, 2010a; 
Gearhart & Bouchard, 2010b), alterations in calcium signaling could play a major role in 
HBV-induced HCC. Many alterations of cell cycle regulatory proteins that have been 
identified in HCC are similar to alterations in cell cycle pathways that have been observed in 
primary hepatocytes when HBx is expressed in the absence of other proteins and in the 
context of HBV replication (Biden et al, 1997; Burkhart & Sage, 2008; Csepregi et al, 2010; 
Deane et al, 2001; Gearhart & Bouchard, 2010a). There are numerous ways in which HBx 
regulation of hepatocyte proliferation pathways could influence HCC development. For 
example, down-regulation of p16 by HBx enabled hepatocytes to evade senescence, a potent 
tumor suppressive mechanism (Kim et al, 2010). Overexpression of cyclin D1 promotes 
hepatocarcinogenesis (Deane et al, 2001), and HBx-mediated upregulation of cyclin D1 
could affect the development of liver cancer. Stimulation of HBV replication by modulating 
the cell cycle could, in itself, generate a more inflammatory environment due to higher 
levels of HBV replication; increased inflammation could enhance the oncogenic 
environment in the liver. Overall, the HBx-mediated induction of cell cycle entry of 
quiescent primary hepatocytes during the course of a chronic HBV infection could alter the 
physiology of hepatocytes to favor carcinogenesis, and signal transduction pathways 
activated by HBx, including pathways involved in cell proliferation and survival, have been 
implicated in hepatocarcinogenesis [(Chen et al, 2010; Chung et al, 2004; Hsieh et al, 2011); 
reviewed in (Ierardi et al, 2010; Rodrigues & Barry, 2011; Thompson & Monga, 2007; 
Torbenson et al, 2004; Whittaker et al, 2010)]. In addition, in the context of an inflammatory 
environment where HBV-infected hepatocytes are being destroyed by inflammatory 
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responses, any mechanisms that inhibit regeneration, such as HBx induction of p21 or p27, 
might eventually lead to compensatory mechanisms that select for cells that have become 
resistant to anti-proliferative signals. Repeated cycles of forced hepatocyte regeneration 
occurring in the context of the inflammatory environment of an HBV-infected liver could 
eventually contribute to HCC development. 
4.6.2 Future directions 
While recent studies are beginning to define the activities of HBx in normal hepatocytes, in 
the livers of small animal models, and in the context of HBV replication, the precise 
molecular mechanisms that underlie many HBx activities remain unknown and should be 
the focus of future studies. Although a bewildering array of functions have been linked to 
HBx expression, these activities may simply reflect the cell-specific consequence of a limited 
number of initiating events that are controlled by a small number of primary HBx activities. 
Due to the paucity of available model systems for studying direct HBV infections and the 
low level of HBx expression during HBV replication, identifying HBx activities during HBV 
replication in authentic normal human hepatocytes will likely remain a challenge. Studies in 
other model systems such as cultured primary rodent hepatocytes will provide valuable 
models for characterizing HBx activities in normal hepatocytes. The major focus of this 
chapter has been HBx regulation of calcium signaling and cell proliferation pathways and 
how these HBx activities regulated HBV replication and may influence the development of 
HCC; consequently, in the following section we will focus on potential future directions that 
are relevant to these HBx activities.  
The role of the Pyk2/FAK-Src-Ras-Raf-MAPK pathway in HBx regulation of hepatocyte 
proliferation pathways remains unexplored and an important future area of investigation. 
HBx stimulation of the Pyk2/FAK-Src-Ras-Raf-MAPK pathway could profoundly affect 
hepatocyte physiology and modulate carcinogenic processes. Results from several studies 
have suggested that expression levels of p21, p27, and cyclin D1 can be regulated by MAPK 
signaling [(Bottazzi et al, 1999; Liu et al, 1996); reviewed in (Kerkhoff & Rapp, 1998)]. 
Importantly, the results of one study in mouse hepatocytes identified a role of prolonged 
MAPK signaling in HBx-induced elevation of p21 and p27 (Qiao et al, 2001). Whether the 
Pyk2/FAK-Src-Ras-Raf-MAPK pathway, which has been linked to HBx elevation of 
calcium, is directly responsible for HBx regulation of hepatocyte proliferation pathways and 
HBV replication in primary hepatocytes awaits further investigation. Additionally, the 
mechanism that underlies HBx regulation of cyclin D1 in normal hepatocytes is unknown. 
The cyclin D1 promoter contains several binding sites for the transcription factor NF-B 
(Hinz et al, 1999), and studies have shown that HBx can activate NF-B in cultured primary 
rat hepatocytes (Clippinger et al, 2009). One study in Chang liver cells suggested that the 
HBx-mediated increase in cyclin D1 expression was caused by HBx activation of NF-B 
(Park et al, 2006); however, whether HBx upregulates expression of cyclin D1 through 
activation of NF-B in a normal hepatocyte has yet to be determined and should be the 
subject of future studies. Activation of the Wnt pathway, inactivation of GSK3-, and 
stabilization of -catenin have also been linked to activation of the cyclin D1 transcription 
promoter [reviewed in (Monga, 2011)], and it was recently shown that HBx can activate the 
Wnt pathway (Cha et al, 2004; Hsieh et al, 2011), increase the phosphorylation and 
inactivation of GSK3- (Cha et al, 2004; Yang et al, 2009), and increase -catenin 
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accumulation in some HCC cell lines (Cha et al, 2004; Hsieh et al, 2011). Whether HBx 
regulates cyclin D1 expression through activation of the Wnt signaling pathway in normal 
hepatocytes and in the context of HBV replication is unknown; inactive GSK3- and 
increased -catenin accumulation are associated with HCC development (Ban et al, 2003). 
An important HBx activity that could also affect cyclin D1 levels and requires further 
investigation is HBx stimulation of DNMT1 expression and the resulting elevation of 
methylation of the p16 promoter and decreased p16 expression; this HBx activity was linked 
to elevation of cyclin D1 and phosphorylation of Rb in HepG2 cells (Jung et al, 2007; Zhu et 
al, 2007). Although HBx regulation of p16 levels in cultured primary rat and human 
hepatocytes was linked to calcium signaling (Gearhart & Bouchard, 2010a), the possible role 
for DNMT1 in decreased expression of p16 was not assessed in these studies and could have 
important implications for HCC development.  
The interaction of p53 and HBx, whether direct or indirect, remains a subject of considerable 
debate, and a comprehensive analysis of precisely how HBx or p53 each affects activities of 
the other protein could provide important insights into mechanisms that link HBV 
infections and HBx expression to HCC development. Although p53 stimulation of p21 
expression has been extensively characterized (el-Deiry et al, 1993), whether p53 affects HBx 
regulation of p21 and hepatocyte proliferation pathways in normal hepatocytes and in the 
context of HBV replication remains to be determined. Interestingly, HBx was shown to 
induce p21 expression in a both a p53-dependent and independent manner (Ahn et al, 2002; 
Park et al, 2000). An important focus of future studies should be a comprehensive analysis 
of the interplay between HBx and p53 activities in normal hepatocytes and how this 
influences HBV replication and the development of HCC-associated HCC.  
Although the future studies described above would address the impact of HBx expression 
on hepatocyte physiology, an equally important focus for future studies is to determine 
precisely how HBx modulation of the cell cycle directly affects HBV replication. Studies in 
primary rat hepatocytes have clearly shown that hepatocyte exit from G0 and subsequent 
arrest in G1 is required for HBV replication and for activation of the HBV polymerase 
(Gearhart & Bouchard, 2010a; Gearhart & Bouchard, 2010b); however, exactly how this HBx 
activity stimulates the polymerase remains unknown. Moreover, effects of cell cycle 
modulation on other HBV proteins that are required for HBV replication have not been 
investigated. The HBV core protein is phosphorylated on three serine residues; differential 
phosphorylation of these serines is required for various stages of HBV replication (Melegari 
et al, 2005). Whether HBx regulation of the cell cycle affects core phosphorylation in normal 
hepatocytes and whether this modulates HBV replication remains to be explored. The 
results of several studies have identified putative candidate kinases that are responsible for 
these phosphorylation events (Daub et al, 2002; Duclos-Vallee et al, 1998; Kann & Gerlich, 
1994; Yeh et al, 1993); however, the events and kinase(s) that result in the phosphorylation of 
HBV core in hepatocytes are generally not well understood. It is possible that the kinase 
responsible for phosphorylation of the HBV core protein is activated by the HBx regulation 
of hepatocyte proliferation pathways, and specifically identifying this kinase(s) in HBV-
infected hepatocytes will be an important focus of future studies. Finally, the upregulation 
of the R2 subunit of ribonucleotide reductase by HBx, and the dependence of HBV 
replication on upregulation of R2 expression suggest that HBx may cause cell cycle entry in 
order to increase the availability of dNTPs. Recently, it was shown that HBV can increase 
the cellular concentration of dNTPs in HepG2.2.15 cells, as compared to HepG2 cells (Cohen 
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et al, 2010). Although these findings are intriguing, this increased pool of dNTPs was not 
directly linked to HBx and not confirmed in HBV-infected normal hepatocytes. 
Consequently, an important subject of future studies should be to determine whether an 
increase in dNTP concentration is the ultimate goal of the HBx-mediated cell cycle 
modulation and whether dNTPs are a limiting factor during HBV replication in hepatocytes. 
Ribonucleotide reductase could be a new drug target to inhibit HBV replication in HBV-
infected individuals; recent studies have shown that inhibition of the R2 subunit of 
ribonucleotide reductase can reduce the growth potential of cancer cells (Heidel et al, 2007). 
Overall, the results of future studies that address HBx activities in authentic hepatocytes and 
in the context of HBV replication should focus on identifying primary HBx activities, 
thereby generating potential new therapeutic targets to inhibit HBV replication and the 
development of HBV-associated HCC.  
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